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Abstract 
Abstract 
 
Eukaryotic and prokaryotic cells can release vesicles into the biological fluids that 
differ in size and mechanism of biogenesis. In recent years, particular attention has been 
paid to exosomes which are naturally occurring nanoparticles (50 – 150 nm) that have 
been found in various biological fluids and are recognized as having an important role in 
intercellular communication and other biological processes. Human mesenchymal stem 
cells (hMSCs) are multipotent cells that can be found in different tissues in the adult. 
hMSCs have a large capacity for ex vivo expansion and show immunosuppressive 
properties, making them the ideal source of exosomes for biomedical applications.  
Dendrimers are nanoscale molecules that have promising properties as 
drug/gene delivery vehicles and, as such, their inclusion inside hMSCs exosomes may 
be a way for their easier spreading and target reaching in the body. The present work 
was focused on the hypothesis that exosomes can be loaded before their isolation from 
cells by simple cell exposure to dendrimers. First, dendrimers were labelled with 
rhodamine and then characterized by 1H NMR, FTIR, UV/Vis spectroscopy, and 
fluorescence spectroscopy. Then, the effect of the pH in the stability of the fluorescence 
emission of these conjugates was study, as well as their cytotoxicity behavior and 
kinetics of cellular internalization. After, a protocol for exosome isolation was established 
using a precipitation-based approach and the isolated exosomes were characterized by 
DLS, TEM and acetylcholinesterase activity. hMSCs were then exposed to a solution 
containing the labelled dendrimers and the released exosomes were collected to 
evaluate the presence of the dendrimers inside. Contrary to what was expected, the 
dendrimers were not excreted inside exosomes and, instead, were accumulated in the 
cellular perinuclear zone. By fluorescence microscopy and using specific biochemical 
markers, it was possible to co-localize the conjugated dendrimers with the Golgi complex 
and the endoplasmic reticulum. 
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Resumo 
 
As células eucariotas e procarióticas podem libertar vesículas nos fluidos 
biológicos que diferem no tamanho e mecanismo de biogénese. Os exossomas, 
nanopartículas de ocorrência natural (50 - 150 nm), podem ser encontrados em diversos 
fluidos biológicos e possuem um papel importante na comunicação intercelular e noutros 
processos biológicos. As células estaminais mesenquimais humanas (hMSCs) são 
células multipotentes que podem ser encontradas em diferentes tecidos adultos, que 
possuem uma larga expansão ex vivo e propriedades imunossupressoras. 
Os dendrímeros são moléculas com tamanhos nanométricos que possuem 
propriedades promissoras para a entrega de fármacos/genes e, como tal, a sua inclusão 
dentro de exossomas derivados de hMSC poderá representar uma maneira de facilitar 
a sua circulação no corpo de modo a atingirem os alvos biológicos. O presente trabalho 
focou-se na hipótese de que os exossomas podem ser carregados por simples 
exposição das células às soluções de dendrímero.  Primeiro, os dendrímeros foram 
marcados com rodamina e caracterizados utilizando 1H RMN, FTIR, espectroscopia 
UV/Vis e espectroscopia de fluorescência. Depois, estudou-se o efeito do pH na 
estabilidade da emissão de fluorescência desses conjugados, bem como o seu 
comportamento de citotoxicidade e cinética de internalização celular. Seguidamente, os 
exossomas foram isolados por precipitação através da utilização de um reagente 
comercial e caracterizados por DLS, TEM e pela atividade da acetilcolinesterase. As 
hMSCs foram então expostas a uma solução contendo os dendrímeros e os exossomas 
libertados foram colhidos e avaliados de maneira a determinar a presença de 
dendrímeros no seu interior. Ao contrário do que era esperado, os dendrímeros não 
foram excretados dentro dos exossomas e, em vez disso, ficaram acumulados na região 
perinuclear das células. Por microscopia de fluorescência e utilizando marcadores 
bioquímicos específicos, foi possível co-localizar os dendrímeros conjugados com o 
complexo de Golgi e o retículo endoplasmático. 
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1. Introduction  
 
1.1. Extracellular vesicles (EVs)  
 
Intercellular communication is a crucial and important aspect in multicellular 
organisms. Communication among cells can occur by direct contact, through adhesion 
molecules and gap junctions, or by mediation of soluble factors, such as cytokines, 
growth factors and hormones [1]. In the last two decades, a third mechanism is being 
elucidated, consisting of the intercellular transfer of extracellular vesicles (EVs), at short 
and long distances [2,3]. These membrane-based structures serve as vehicles to carry 
different types of cellular cargo to recipient cells, like lipids, proteins and nucleic acids 
[4]. 
The term “extracellular vesicle” was recently introduced and is being used for the 
description of any type of membrane vesicle secreted into the extracellular milieu, 
independently of their biogenesis and composition. All cells produce EVs, including those 
of prokaryotic organisms [5]. EVs have been traditionally classified based on their cell or 
tissue of origin. For example, prostasomes are derived from prostate cells and 
oncosomes from tumour cells [1]. These EVs can be distinguished based on their size, 
mechanism of biogenesis, buoyant density, and so on. A recent classification of EVs 
based on their biogenesis pathway or intracellular origin led to  three different subsets of 
these structures: apoptotic bodies, ectosomes (or microvesicles) and exosomes [6], 
which are represented in Figure 1.       
 
 
 
 
 
 
 
Figure 1 – Origin of the different types of EVs. Apoptotic bodies are formed in the late stage of programmed 
cell death (apoptosis). Ectosomes (or microvesicles) are formed through the outward shedding of the plasma 
membrane. Exosomes are released upon the fusion of multivesicular bodies with the cell membrane. Figure 
from reference [7].  
     
Ectosomes 
(100-2000 nm) 
Apoptotic bodies 
(1-4 µm) 
Exosomes 
(50-150 nm) 
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1.1.1. Apoptotic bodies  
 
Apoptosis is the process of cell death and may occur in both normal and cancer cells. 
This mechanism has different stages, starting by nuclear chromatin condensation, 
followed by membrane blebbing and finishing in the incorporation of cellular content into 
membrane vesicles called apoptotic bodies or apoptosomes [8]. Apoptotic bodies are 
generally the biggest EVs, with sizes around 500 – 4000 nm, and are characterized by 
having organelles inside. However, smaller vesicles (50 – 500 nm) can be released in 
this process too [9].  
Normally, most of the apoptotic bodies are phagocytosed by macrophages and 
locally cleared upon their formation (Figure 2). This process is mediated by the 
establishment of specific interactions between receptors in the phagocyte membrane 
and ligands at the apoptotic body membrane. One of the best characterized events in 
the apoptosis mechanism is the translocation of phosphatidylserine to the outer part of 
the lipid membrane. When phosphatidylserines are translocated, they can bind to 
Annexin V, and therefore be recognized by phagocytes [10]. Other well characterized 
change in the apoptotic process is the oxidation of proteins localized at the membrane 
surface. These oxidation sites can bind to thrombospondin and C3b, and thus be equally 
recognized by phagocytes [11]       
 
 
 
 
 
Figure 2 – The formation of apoptotic bodies during programmed cell death (apoptosis) and their 
phagocythosis. Tsp: Trombospondin; C3b: Large element formed by the cleavage of complement 
component 3. Figure adapted from reference [12]. 
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1.1.2. Ectosomes or microvesicles 
 
Microvesicles, also known as ectosomes, result from direct shedding of the cell 
membrane (13). Relative to exosomes, microvesicles normally have a bigger size, 
around 50-2000 nm. Although there is an overlap between the size range of these two 
types of EVs, their main difference is the underlying biogenesis mechanism.[13].  
The formation process of microvesicles results from different factors, such as 
cytoskeletal protein contraction and phospholipid redistribution. The cell membrane has 
a heterogenous distribution of proteins and phospholipids, forming micro-domains. This 
heterogeneity is regulated by the aminophospholipid translocase. This enzyme, also 
known as flippase, is responsible for the transportation of phospholipids from the outer 
to the inner side of the cell membrane, whereas floppases transfer phospholipids from 
the inner to the outer side of the cell membrane. It is reported that membrane 
shedding/microvesicle formation is induced by the translocation of  phosphatidylserine 
to the outer side of the cell membrane [14] and that the shedding process is completed 
through contractions of  cytoskeletal structures resulting from actin-myosin interactions 
[15].   
The content of microvesicles seems to be enriched in a set of proteins. For example, 
these melanoma microvesicles were enriched in B1 integrin receptors and other 
membrane proteins, such as the vesicle-associated membrane protein 3 (VAMP3) [15]. 
However, the transferrin receptors, highly present in exosomes, do not seem to appear 
in microvesicles [16].                 
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Figure 3 – The process of microvesicle/ectosome biogenesis. In a melanoma model, the overexpression of 
the Guanosine triphosphate (GTP)-binding protein Adenosine diphosphate (ADP)-ribosylation factor 6 
(ARF6), a Rho family member, resulted in microvesicle secretion increase. The activated ARF6 starts a 
signal cascade, first with phospholipase D (PLD) activation and finishing by phosphorylation and activation 
of the myosin light chain, like showed in Figure 3. These signalling cascade events do not alter the formation 
and secretion of smaller vesicles, like exosomes, which supports the fact that the biogenesis of microvesicles 
is distinct from that of exosomes; ERK: Extracellular signal-regulated signal; MLCK: Myosin light-chain 
kinase. Figure adapted from reference [12]. 
 
1.1.3. Exosomes   
 
In 1983, Harding et al followed the cell uptake of gold-labelled transferrin through a 
clathrin-mediated endocytosis process in rat reticulocytes. They reported that the gold-
labelled transferrin accumulated inside vesicles which existed inside non-lysosomal 
endosomes referred as multivesicular bodies. These multivesicular bodies then fused 
with the plasma membrane and released their inner vesicles by exocytosis [17]. The term 
exosome was introduced by Johnstone et al in 1987, to refer to these released vesicles 
[18]. They observed that during the process of reticulocyte maturation, there were large 
sacs inside the cells containing small vesicles (exosomes). Then, they also labelled the 
transferrin receptor with gold nanoparticles, and observed the fusion of the large sacs 
with the cell membrane and subsequent release of the small vesicles into the 
extracellular environment [19].  
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1.1.3.1. Origin and molecular composition of exosomes    
 
Exosomes have been discovered in a variety of supernatants from different cell lines 
in culture, and are present in all the human fluids, which suggests that all cells have the 
potential to produce them [20]. Exosomes are nano-sized vesicles with a diameter of 50-
150 nm, formed by the endocytic cellular pathway which can be separated into three 
stages: (i) the first stage corresponds to plasma membrane invagination to form the 
endocytic vesicles; (ii) in the second stage, the inward budding of endosomal membrane 
starts giving rise to multivesicular bodies (MVBs); (iii) in the last and third stage, MVBs 
fuse with the plasma membrane and release their vesicular content (exosomes) [21]. 
These steps are shown in Figure 4.  
As mentioned before, endocytic vesicles are created from the invagination of the 
plasma membrane, creating what are called “endosomes”, which mature and become 
late endosomes. Then, through the inward budding of these late endosomes, vesicles 
are accumulated in the endosomal lumen. The accumulation of these vesicles inside late 
endosomes leads to the formation of multivesicular bodies (MVBs). The MVBs can either 
fuse with lysosomes for degradation of their content or fuse with the plasma membrane, 
releasing their intraluminal vesicles (ILVs) in the extracellular space, where they become 
known as exosomes The main difference between these pathways relies on the action 
of  protein sorting complexes known as endosomal sorting complexes required for 
transport (ESCRT) [22].   
 
 
 
 
 
 
 
 
Figure 4 – Biogenesis of exosomes. Figure adapted from reference [12] 
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The ESCRT machinery consists of four multi-protein complexes, namely ESCRT-0, 
ESCRT-I, ESCRT-II and ESCRT-III. These complexes are recruited to sort a set of 
specific proteins into ILVs. The process is known to require ubiquitination of the cytosolic 
tail of endocytosed receptors [23]. These cargos constitute proteins that will be 
incorporated into ILVs and later become part of the exosomes released. For example, 
the protein codified by the tumour susceptibility gene 101 (TSG101), a component of 
ESCRT-I, forms a complex with the ubiquitinated cargo protein, and helps in the 
activation of ESCRT-II, inducing endosomal membrane budding. This complex is then 
involved in the sequestration of MVB proteins and the recruitment of the deubiquitination 
enzyme to remove ubiquitin from the cargo proteins before sorting them into the ILVs. 
Then, at last, the ESCRT-III is disassembled by the vacuolar protein sorting-associated 
protein 4 (VPS4) adenosine triphosphatase (VPS4 is an ATPase) [24].   
The nano-spherical membrane of exosomes is formed by a bilayer of lipids. The 
membrane contains a set of diverse types of lipids and proteins (Figure 5), which are 
related to the parent cells from which exosomes are released. According to ExoCarta, 
an exosome database, there are currently 8000 proteins and 194 lipids known to be 
associated with exosomes [25].  
Since exosomes are originated from endosomes, they contain multiple families of 
proteins, such as tetraspanins (CD63, CD81, CD9), heat shock proteins (Hsp70), 
lysosomal proteins (Lamp2b), and fusion proteins (CD9, flotillin, Annexin), as shown in 
Figure 5. Tetraspanins have received a high attention, because of the use of the trinity 
CD63, CD81 and CD9 as exosome markers. However, as mentioned before, the 
existence of a single exosome-specific protein remains to be disclosed [26]. Besides 
proteins and lipids, exosomes also contain biologically active nucleic acids, especially 
ribonucleic acid (RNA), demonstrating their ability to mediate the horizontal transfer of 
genetic material. The existence of two types of RNA inside exosomes, specifically 
messenger RNA (mRNA) and micro RNA (miRNA), has also been demonstrated  [27].   
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Figure 5 – Biochemical composition of exosomes. Figure adapted from reference  [28]. 
 
1.1.3.2. Biological functions of exosomes 
 
Exosomes circulate in the body through different biofluids, such as saliva, serum, 
urine, blood, synovial fluid and breast milk, which suggests that these EVs play an 
important role in the intercellular communication and biological responses. There are 
some examples of the biological roles that exosomes can play in the body, like the 
removal of unnecessary proteins from cell maturation processes. One factor that affects 
the biological response of exosomes is their cellular origin. Some studies demonstrated 
that exosomes secreted from antigen presenting cells can have the ability to express, 
and have at their surface, both the major histocompatibility complex (MHC) I and II. 
These complexes help in the activation of CD8+ and CD4+ T-cells to trigger specific 
immune responses [29]. Besides the delivery and exchange of proteins and lipids among 
different cells, exosomes can transport some types of nucleic acids, as mentioned 
before. For example, there are studies reporting the secretion of mRNA and small RNA 
by mast cells in exosomes, which were then translated in the recipient cells [30].     
Besides their role in normal biological responses and processes, exosomes seem to 
be involved in many diseases. For example, in cancer, it seems that exosomes can 
induce or facilitate the development of a tumoral microenvironment with the transfer of 
mRNA and some proteins to distant cells. One example is the mutant Kirsten rat sarcoma 
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(kRAS) viral oncogene protein and the c-Met oncoprotein that promote tumour cell 
proliferation, thrombosis and angiogenesis [31,32].  
Like it was mentioned before, exosomes can be isolated from a variety of cells, and 
given the fact that these EVs participate in intercellular communication and in the 
maintenance of normal and pathological conditions, there are several studies regarding 
their use for diagnostic and therapeutic purposes. For example, exosomes were used to 
detect tumours in patients with ovarian, prostate and breast cancer [33–35]. Some of 
these applications and therapeutic effects are schematized in Figure 6. Regarding the 
use of exosomes in therapeutics, these vesicles can induce tissue regeneration with the 
delivery of lipids, proteins, growth factors and nucleic acids, for example [36].     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – The role of exosomes in different tissues and their possible therapeutic applications. Figure 
adapted from reference [29].    
 
1.1.4. International Society for Extracellular Vesicles position in the definition of 
extracellular vesicles 
 
The extracellular milieu, like serum and plasma, may be very complex and contain a 
diversity of non-vesicular materials such as extracellular RNA, protein complexes and 
lipoproteins. Separation of these non-vesicular materials from EVs is not fully achieved 
by common isolation protocols, like ultracentrifugation and commercial precipitation kits. 
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Consequently, there is a need to determine the distinct contributions of EVs in any 
experiment that describes the molecular content or the functional role of the isolated 
material. So, the ISEV (International Society for Extracellular Vesicles) has adopted a 
set of requirements that researchers can use to discriminate EV from non-EV 
components [37]. One of the first requirements to define EVs is that they should be 
isolated from extracellular fluids, like conditioned cell culture medium or body fluids. 
Here, an important aspect is that the collection of EV-containing fluid must be gentle, 
limiting cell disruption, which may contribute to the isolation of vesicles from the 
intracellular compartments. The second requirement regards to the characterization of 
these EVs is that a general overview of their protein composition must be provided, 
including description or quantification of necessarily expected proteins, like those shown 
in Table 1. ISEV suggested that investigators should report at least 3 or more proteins 
(and, at least, in a semi-quantitative manner) expected to be present in the EVs of 
interest, like transmembrane proteins and proteins from the cytosol that were linked to 
the membrane (Table 1, groups 1 and 2, respectively). The amount of proteins not 
expected to be present in EVs should also be determined, such those associated with 
cellular structures different from the cell or endosome membranes (Table 1, group 3). 
Furthermore, protein isolates should be compared with those described for other EVs, 
by searching within databases, like EVpedia and Vesiclepedia. The presence of 
extracellular proteins (Table 1, group 4) in EVs preparations should be regarded very 
carefully. For example, acetylcholinesterase (AChE) has been used as a EV marker but 
ISEV requires confirmation of the presence of this protein by other techniques such as 
Western blotting or by performing assays where inhibitors of AChE are used. The third 
and last requirement for the definition of EVs, is the characterization of single vesicles 
within a mixture to get information on the heterogeneity of the EV preparation. As a rule, 
at least 2 different technologies should be used to characterize individual EVs. When 
using electron microscopy (EM) or atomic force microscopy (AFM), images should show 
a wide field (so that several vesicles can be observed) and high-magnification images of 
individual vesicles. Size distribution measurement of EVs obtained, for example, by 
nanoparticle-tracking analysis, dynamic light scattering or resistive pulse sensing, may 
also provide valuable information, representative of the whole EV population. However, 
the results acquired using these techniques should be compared with data from 
transmission EM (TEM), AFM or other microscopy techniques, since they are not able to 
distinguish between vesicles and other particles of similar size [37].   
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Table 1 – Different proteins expected in EVs isolates, including some examples (non-exclusive). Adapted 
from reference [37]. 
 
 
 
 
 
 
 
 
 
 
 
1.2. Exosome isolation methods 
 
The techniques used in the isolation of exosomes should have a high efficiency, 
independently of the sample source. After, the quality of the exosome suspensions 
should be analysed by several physical and chemical/biochemical techniques [38]. With 
the fast evolution of science and technology, different techniques have been developed 
for the isolation of exosomes that are able to provide a high quantity of these vesicles 
with a elevated degree of purity. Each technique has a set of unique advantages and 
disadvantages for exosome isolation, and these will be discussed in the next sections.    
 
1.2.1. Ultracentrifugation-based isolation techniques 
 
  When a suspension is submitted to a centrifugal force, the particles in the 
suspension will sediment according to their physical properties, such as the size, density 
and shape. The sedimentation process will also depend on the applied centrifugal force, 
as well as on solvent density and viscosity. Normally, in ultracentrifugation processes, 
one can reach high centrifugal forces, up to 1 000 000 x g. The ultracentrifugation-based 
approaches are the gold standard for exosome isolation, accounting for 56 % of the 
exosome isolation reports [39]. Exosomes can be isolated by preparative 
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ultracentrifugation. There are two types of preparative ultracentrifugation, the differential 
ultracentrifugation and the density gradient ultracentrifugation. 
 The differential ultracentrifugation is based on the use of different centrifugation 
cycles at different centrifugal forces and periods of time to isolate exosomes from other 
components in a sample. Before exosome isolation, normally a clean-up step is carried 
out to remove large particles from plasma or serum [40]. Between the centrifugation 
cycles, and depending on the centrifugal force used, the pellet or the supernatant is 
resuspended in an isotonic solution, such as Phosphate buffered saline (PBS). This 
method normally is referred as the pelleting or the simple ultracentrifugation method [41]. 
 In the density gradient ultracentrifugation, separation of exosomes is 
accomplished according to their mass, density and size in a density gradient medium 
pre-constructed in a centrifuge tube. The sample is layered in the top of the tube 
containing the gradient and then submitted to an extensive ultracentrifugation. After 
applying a specific centrifugal force, the solutes, including the exosomes, move to 
different zones, according to their specific sedimentation rate. Then, the exosomes can 
be recovered by a simple fraction collection [41].                    
  
1.2.2. Precipitation-based approaches 
 
  Water-excluding polymers, such as polyethylene glycol (PEG), can be used to 
alter the solubility or dispersability of exosomes, and consequently, the precipitation of 
these vesicles in biological fluids [42]. This water-excluding polymers act by tying up the 
water molecules and forcing less soluble components to precipitate [42,43]. Normally, 
the samples are incubated with PEG having a molecular weight of 8 kDa [44]. Then, after 
incubation at 4ºC overnight, the samples are centrifuged at low speeds and the 
exosomes pelleted [42]. The precipitation is easy and does not require the use of 
expensive and specialized equipment [45].  
 There are several exosome precipitation kits in the market for different biofluids, 
such plasma, serum, urine, ascites, cerebrospinal fluid and culture medium. However, 
before precipitation, the samples need to be pre-cleaned from different interferents, such 
whole cells and cellular debris. Also, one disadvantage of the polymer-based 
precipitation is the co-precipitation of other contaminants, such as proteins and polymeric 
materials [39]. The use of pre- and post-isolation steps can reduce these problems. The 
pre-isolation steps can be used to remove particles, such as lipoproteins, and the post-
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isolation steps to remove polymeric materials with the use, for example, of a Sephadex 
G-25 column, for example.   
 
1.2.3. Immunoaffinity capture-based techniques 
 
   Due to their natural and cellular biogenesis, exosomes have a highly diverse set 
of proteins and receptors both in the lumen and membrane. This offers the possibility for 
the development of high selective isolation techniques, based on the interaction between 
those proteins (antigens) and their antibodies. Normally, the exosome biomarkers used 
in immunoisolation are localized in the exosome membranes.  
 For example, a microplate-based enzyme-linked immunosorbent assay (ELISA) 
was developed for the capture and quantification of exosomes from urine, plasma and 
serum [39]. Other variants based on immunoaffinity capture were developed. For 
example, Zarovni et al. [39] used submicron-size magnetic particles coated with specific 
antibodies for the isolation of exosomes from cell culture. The CD63 membrane protein, 
that is highly expressed in most of human exosomes, was the first characterized member 
of the tetraspanin family [43,46]. Having this is mind, this surface protein became of high 
interest in the development of immunoisolation techniques for exosomes in complex 
sample matrices. Some investigations suggested that immunoaffinity-based isolation 
techniques have a higher efficiency in the isolation of exosomes from human colon 
cancer cell culture media compared to ultracentrifugation techniques [47]. In comparison 
to the microplate-based technique, the use of magnetic beads for the immunoisolation 
of exosomes is more efficient and sensitive due to the a larger surface area available for 
interaction and a more homogenous capture process. Also, the starting sample volume 
in magnetic-based isolation approaches does not represent an imposition, and this kind 
of approach can be applied to a diverse set of sample volumes. 
 
1.2.4. Microfluidics-based isolation techniques 
 
      The advances in the microfabrication technologies led to the development of 
microfluidics-based devices for the efficient and quick isolation of exosomes. These 
devices mainly work based on the physical and biochemical properties of exosomes at 
the microscale, like their size, density and immunoaffinity. Other innovative mechanisms 
are also being proposed for microfluidics-based exosome isolation that involve 
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electrophoretic and electromagnetic manipulations [48], as well as acoustic processes 
[49].  
 To increase the specificity and the possibility of studying subpopulations of 
exosomes, Chen et al. [50] tried to integrate the use of immunoaffinity capture in a 
microfluidic chip for the isolation of exosomes. Like it was mentioned before, this 
immunocapture technique relies in the interaction between the exosome membrane 
proteins (antigens) and the antibodies immobilized on the chip. There are already some 
microchips commercialized for exosome capture, specifically the ExoChip. The ExoChip 
is a microfluidic device functionalized with tetraspanin CD63, a largely expressed protein 
in the human exosomes surface. Then, a fluorescent carbocyanine dye (DiO) stains the 
membrane of exosomes, and the quantification is performed with the use of a microplate 
reader. The experimental design of this chip is summarized in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Experimental design of the ExoChip. (a) The first chip designed for the isolation of exosomes. 
(b) A modified design of the same chip, the ExoChip with a single channel (W = 0.75 mm, L = 73 mm, P = 9 
mm, H = 100 μm). (c) Experimental scheme of a 3 channel ExoChip. (d) Working scheme of the ExoChip, 
which involves three steps: (i) the capture of CD63-positive exosomes from a blood infusion. (ii) staining with 
the DiO fluorescent dye and (iii) Chip analysis with conventional methods. Figure adapted from reference 
[51].      
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1.3. Characterization of extracellular vesicles 
 
Due to the complexity of EVs structure and composition, there is a need for the 
development of methods capable of a) characterizing their biochemical content and b) 
determining their physical properties. The biomolecular characterization of EVs involves 
the determination of their protein, nucleic acid and lipid content, while the physical 
characterization involves the determination of parameters such as morphology, size, 
charge, mechanical properties and density. Together, these characteristics can give us 
information about the biological function and origin of EVs. 
 
1.3.1. Physical characterization of EVs 
 
In the last decades, there was a great attention towards the physical characterization 
of small EVs, because there was an enormous development in techniques that can 
detect objects with a size below 200 nm. In this section, the physical techniques that are 
currently more often used in the physical characterization of EVs will be described.  
 
1.3.1.1. Dynamic light scattering 
 
Dynamic light scattering (DLS) technique is the most used optical technique for the 
determination of nanoparticles size in solution. This technique is based on the incidence 
of a laser beam in a colloidal solution, where there is dispersion of this light by 
nanoparticles in the solution, resulting in fluctuations of the scattered light intensity. 
These nanoparticles are under Brownian motion effect, which is related to their 
hydrodynamic size. So, it is possible to determine particle size distribution through a 
mathematical formula, known as the Stokes-Einstein equation. It is important to refer that 
this equation assumes that all the nanoparticles are spherical. This technique can detect 
particles and vesicles with nanoscale sizes, which makes this technique suitable for the 
characterization of EVs [52,53]. One of the limitations of DLS is that it does not work that 
well with polydisperse samples, because the larger objects can scatter more light and 
may hide the smaller particles [54]. For the characterization by DLS, EVs can be isolated 
from cell culture medium [54,55] or from plasma samples [56].  
To overcome some of the limitations that were mentioned, the samples can be 
submitted to size exclusion chromatography, in order to remove the bigger particles or 
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aggregates, like proteins or larger vesicles, making the technique more suitable for the 
EV population under study [57]. 
 
1.3.1.2. Nanoparticle tracking analysis 
 
The nanoparticle tracking analysis (NTA) has recently been used as an alternative 
technique to DLS for the determination of EVs size, especially for the smallest ones, like 
exosomes. The NTA technique is similar to DLS since it also detects the scattered light 
of particles with the use of a laser beam. However, the NTA technique uses a 
conventional microscope, allowing the direct visualization of the light scattering particles 
(Figure 8). The tracking of the Brownian motion allows the determination of the 
hydrodynamic size of single particles [58].  
 
 
 
 
 
 
 
    
Figure 8 – Representation of the nanoparticle tracking analysis (NTA) technique. Figure adapted from 
reference [58]. 
 
One of the advantages of this technique in relation to DLS, is the fact that the 
concentration of particles can be measured. Also, NTA is more suitable for the analysis 
of polydisperse samples, because particles are analysed in an individual basis, instead 
of the ensemble-average signal used in DLS.  
One of the limitations of NTA is the fact that small particles scatter few light, making 
this technique only suitable for particles with a size bigger than 50 nm [59,60]. Another 
limitation is the analysis of vesicles in complex biological samples, which cannot be 
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distinguished from other kind of particles, like protein aggregates [57,61]. Nevertheless, 
NTA remains a convenient and fast technique in the characterization of EVs [61,62].   
 This technique has been used in diverse studies, for example, in the 
determination of EVs sample stability and quality [63], and in the characterization of EVs 
found in blood samples of cancer [64] and Parkinson´s disease patients [65,66].     
 
1.3.1.3. Tunable resistive pulse sensing 
 
 Electrical methods, based on the Coulter principle, have been proposed as an 
alternative to optical methods for the size determination of EVs. Normally, the setup of 
these electrical techniques is based in two chambers filled with an electrolyte solution 
that are separated by a pore. The passage of a nanoparticle through the pore results in 
the decrease of the ionic conductivity across the aperture, referred as blockade event 
(Figure 9). The amplitude of the blockade event is related to the particle volume.  
 
 
 
 
 
 
 
 
 
 
Figure 9 – Tunable resistive pulse sensing (A) Sectional scheme of a pore. The sample is normally placed 
in the upper fluid cell. (B) Example of a baseline and blockade event (current dips) that are caused by the 
passage of a particle through the pore. Each event is analysed for full width half maximum (FWHM) duration, 
related to the particle surface charge, and Δip, related to the particle volume. (C) The Izon qNano instrument, 
showing the fluid cell, teeth and the membrane with the aperture. Figure adapted from reference [67]. 
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This technology, referred as tunable resistive pulse sensing (TRPS), can detect 
vesicles down to 50 nm, using, for example, the qNano device, commercialized by Izon 
[68–70]. One of the major advantages of this technique is the use of an elastic pore, 
which size can be tuned to increase the detection range for bigger particles, making this 
technique suitable for polydisperse samples. This technique has already been used in 
the characterization of EVs in many contexts. For example, Böing et al. [71] used TRPS 
to investigate the role of caspase-3 in the production of EVs from breast cancer cells. 
 
1.3.1.4. Flow cytometry 
 
  Flow cytometry is a technique that detects both the fluorescence and scattering 
signal from individual particles through the incidence of a laser beam while these 
particles flow through a nozzle.   
 When the light’s wavelength is smaller than the particles, the forward scattering 
light can be used to determine the size of cells. For smaller particles, such EVs, the 
signal can be deconvoluted through their side scattering, if the structure and refractive 
index value are known. However, like it was mentioned before, normally the suspensions 
of EVs are very heterogeneous in size, making this strategy uncertain. So, the calibration 
through the use of beads of known refractive index and size is being suggested for a 
more precise determination of liposome [72] and EV [73] size. As an alternative, the 
membrane of EVs can be labeled with fluorescent probes to determine their size, since 
homogenous membrane staining results in a  fluorescence intensity that is proportional 
to the surface area [74].  
 However, the detection of vesicles with sizes of few manometers remains a hard 
task in conventional flow cytometry [75,76]. Some optimized systems and protocols can 
detect particles with sizes down to 100 nm [75]. These limitations are due to the fact that 
small EVs or particles have a low scattering signal, and can be affected by the Swarm 
effect, where multiple objects are detected just as a single event [77]. 
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1.3.1.5. Atomic force microscopy 
 
The atomic force microscopy (AFM) is a surface imaging technique, that can have a 
sub-nanometer resolution. One of the advantages of this technique is that the 
measurements can be directly done in aqueous environments, like most part of biological 
solutions. This technique is based on the use of a very sharp tip, mounted in the end of 
a cantilever. The interaction between the tip and the sample surface is monitored through 
the deflection of the cantilever. AFM can be used to study the sample topography, but 
also to study other sample characteristics, like its chemical and mechanical properties. 
The topographical images can be acquired by the contact (Figure 10-ii) and non-contact 
mode (Figure 10-iii) [78]. The tapping mode is normally used for the characterization of 
soft particles, such EVs, because the contact mode can result in vesicle deformation and 
rupture. However, when using AFM in the characterization of EVs, one should have 
attention on the sample preparation, specially sample immobilization in the surface [79]. 
Sharma et al. [80] used AFM tips coated with anti-CD63 to show that the increase in tip-
vesicle binding force was related to the increase in the density of this receptor per vesicle 
in patient samples.      
 
  
 
 
 
 
 
 
 
 
 
 
Figure 10 – Atomic force microscopy imaging of extracellular vesicles. I) working principle of AFM. The AFM 
can operate in ii) contact mode, iii) in tapping mode yielding a topographical image of the surface (iv). Figure 
from reference [81]. 
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1.3.1.6. Electron microscopy 
 
Due to their small size, EVs cannot be detected by standard optical microscopy. 
Instead, an electron microscopy (EM) can be used to visualize these vesicles. EM uses 
electrons instead of photons to create images with resolutions down to nanometers. 
Because of this capacity, EM has become the gold method for visualization of EVs, and 
to study their morphology and structure. There are two main EM techniques, the 
scanning electron microscopy (SEM) and the transmission electron microscopy (TEM). 
In the first one, the topographical image of the surface is acquired through the detection 
of secondary electrons originated from the incidence of an electron beam in the sample. 
However, one of the drawbacks of SEM, is that samples must have a conductive surface, 
being necessary, sometimes, to coat the surface with a thin layer of a conductive 
material, like gold. Despite the use of SEM and other variants, in the characterization of 
EVs [63,82], TEM is mostly used. In TEM the samples do not need to have a conductive 
surface, and therefore ultra-thin samples can be directly analysed in transmission mode. 
However, in standard TEM, samples need to be fixated and dehydrated due to the 
applied vacuum. Also, the samples are normally stained for a better contrast and 
visualization. One of the advantages of TEM is the possibility to do immuno-electron 
microscopy. This allows for the detection of specific biomolecules in the outer membrane 
of the EVs with the use of gold-conjugated antibodies. TEM in combination with 
immunostaining has been used to investigate diverse EVs populations [83].       
 
1.3.2. Chemical/Biochemical characterization of EVs 
 
One of the most commonly used methods for the identification of proteins in EVs is 
Western blotting. In this technique, a mixture of proteins is separated based on their 
molecular weight through a gel electrophoresis. Then, the proteins are transferred to a 
membrane of nitrocellulose, Polyvinylidene difluoride (PVDF) or nylon. Membrane sites 
with unbound protein are blocked with a blocking solution, such as Bovine serum albumin 
(BSA) or non-fat dry milk. Then the membrane is incubated with antibodies specific for 
the protein of interest. In this process, a primary antibody labelled with an enzyme can 
be used or, alternatively, a primary antibody will be used first followed by the addition of 
a secondary antibody labelled with an enzyme. The unbound antibody is washed, leaving 
only the antibody bound to the protein of interest. The bound antibody is then detected 
by exposure to a specific substrate, which gives a detectable signal [84].  For a more 
deeper analysis, proteomic approaches, like Sodium dodecyl sulphate-Polyacrylamide 
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gel electrophoresis (SDS-PAGE) or High-performance liquid chromatography (HPLC) 
followed by mass spectrometry can be used [85]. Conde-Vancells et al. [86] have done 
an extensive proteomic characterization of exosomes secreted by hepatocytes using 
both methods. The lipid content of exosomes can also be analysed by lipidomic 
approaches. Llorente et al. [87] did an extensive analysis of  exosome lipid contents and 
of their cells of origin. There are diverse databases, such Vesiclepedia, in which the 
protein and lipid contents of EVs are described [88].    
 
1.4. Mesenchymal stem cells (MSCs) as the source of exosomes 
 
  One important aspect when using exosomes for drug delivery applications is their 
origin, that is, the cell source used for obtaining them. For example, exosomes isolated 
from dendritic cells can be loaded with antigenic peptides for T cell proliferation, and thus 
be of great potential as a vaccine in cancer and infectious diseases [89]. However, 
exosomes derived from dendritic cells are immunogenic, which does not make them a 
suitable vehicle for drug delivery. Thus, the ideal cell source would be one capable of 
producing non-immunogenic exosomes in abundance.  In fact, for drug delivery, it is 
described that the best option is to use  mesenchymal stem cells derived exosomes [90].   
 
1.4.1. Background of mesenchymal stem cells 
 
MSCs are multipotent stem cells that can be found in diverse adult tissues, such as 
adipose tissue, periosteum, liver, lung, spleen, muscle connective tissue, amniotic fluid, 
placenta, umbilical cord blood, dental pulp and aborted foetal tissues [90]. According to 
the International Society for Cellular Society, MSCs must be plastic adherent when 
maintained in standard culture conditions; they must express CD105, CD73 and CD90, 
and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR 
surface molecules. At last, they must be able to differentiate into osteoblasts, adipocytes 
and chondroblasts in vitro [91]. The differentiation potential of MSCs is shown in Figure 
11.  Although several research papers report the differentiation of MSCs towards cells of 
ectoderm and endoderm origin, this is still controversial.  
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1.4.2. Clinical and therapeutic applications of MSCs   
 
Mesenchymal stem cells are the most studied stem cells, with more than 49000 
publications cited in Web of Science since 1900. This could be attributed to their 
application in a wide range of diseases and injuries [92], to their easy availability from 
different tissues (such as bone marrow and fat tissue) and to their capacity for large ex 
vivo expansion [93]. Until 2015, the database of the US National Institutes of Health (NIH) 
registered about 493 MSC-based clinical trials [94]. MSCs have been explored in four 
main fields: local implantation of MSCs to treat local diseases; systemic transplantation 
of MSCs; use of stem cell therapy together with gene therapy; and use of MSCs in tissue 
engineering procedures [92]. Regarding the local implantation of MSCs, these cells were 
shown to be efficient in the treatment of bone diseases [95]. For example, some clinical 
reports demonstrated 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11- The differentiation capacity of MSCs. The figure shows the ability of MSCs to self-renew (curved 
arrow) and to differentiate into mesodermal lineage (solid arrows). The reported capacity to transdifferentiate 
in cells of other lineages (ectoderm and endoderm) is showed by dashed arrows (even though this is still 
controversial). Figure adapted from reference [96]. 
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the capacity of autologous MSCs in the treatment of large bone defects, when injected 
ex vivo [97]. Also, some studies applied MSCs in the repair of cartilage tissue [98]. The 
MSCs can also be used for the treatment of vascular diseases, like vascular ischemia, 
peripheral arterial disease [99] and coronary artery disease [100]. These studies showed 
very good results, but more trials are needed in a bigger number of randomized patients.  
 Beyond the possibility of direct differentiation into different cell types, MSCs are 
able to secret several biochemical factors that have local paracrine and autocrine actions 
(throphic factors), as shown in Figure 12 [101]. For example, the secretion of trophic 
factors led to a reduction in the infarct incidence and improved the cardiac functions in a 
pig model of chronic ischemia [102]. Later, it was shown that  these therapeutic factors 
were released inside membrane vesicle, more specifically in the exosomes [103].       
 
 
 
 
 
 
 
 
Figure 12 – Paracrine factors release by mesenchymal stem cells which may play an important role in 
mitogenesis, angiogenesis, apoptosis and scarring. Figure adapted from reference [104].  
 
1.4.3. Advantages of using MSCs as exosome producers for drug delivery 
 
Mesenchymal stem cells present many features that make them ideal candidates as 
producers of exosomes. For example, these cells present a large ex vivo expansion 
capacity, and since they can be isolated from human adult tissues, their use is ethically 
non-controversial. Also, as there are already several reports that describe the safe 
clinical transplantation of MSCs, one can conclude that the use of exosomes derived 
from these cells will not lead to adverse effects. The administration of human MSC-
derived exosomes in an immunocompetent mouse model for acute myocardial ischemia 
was shown to have therapeutic effects, and without adverse effects [105,106].  
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      One of the most important aspects in the clinical use of MSCs is their ability to 
make use of suppressive and regulatory effects over the innate immune cells and 
independently of their autologous or allogeneic origin [107]. This immunomodulatory 
ability can result in a longer exosome longevity and bioavailability of their therapeutic 
cargo. Another important aspect of the MSCs is their high ex vivo proliferative capacity. 
Although this expansion is finite, some studies were made regarding this question. For 
example, Chen et al. [108] created an immortalized MSC line with the myc oncogene. 
The immortalization compromised the differentiation capacity of these cells but did not 
affect the production and therapeutic effect of the exosomes. The immortalization of 
MSCs could reduce the need for constant new batches of these cells, also reducing the 
need for constant derivation, testing and validation and therefore making the production 
of MSC exosomes more commercially sustainable. One last topic that should be 
addressed related to the use of MSCs as candidates for the production of exosomes is 
that these cells are among the most prolific producers of exosomes [109]. All these 
properties are presented in Figure 13.     
 
 
 
 
 
 
 
 
 
 
Figure 13 – Advantages of using mesenchymal stem cells as a source of exosomes. Figure adapted from 
reference [4].  
 
1.5. Methods for the loading of therapeutic cargo into exosomes 
 
 Exosomes have a lipid bilayer membrane that serves like a natural barrier for the 
protection of their cargo in order for it to not be degraded in the bloodstream. However, 
the presence of this membrane makes exosome loading a challenging task. Indeed, the 
successful delivery of the therapeutic cargo transported by exosomes depends directly 
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on the efficiency of the selected loading method [110,111]. Exosome loading methods 
can be classified in two groups: (1) after EV isolation; and (2) before EV isolation (like 
schematized in Figure 14). A brief description of the most important methods used is 
presented in the following sections. 
 
1.5.1. Exosome loading methods after EV isolation 
 
1.5.1.1. Electroporation 
 
When exosomes (or cells) are submitted to an electrical field, pores can be 
created in the membranes, facilitating the sorting of cargo into the lumen of EVs [112]. 
For example, Alvarez-Erviti et al. [113] loaded small interfering RNA (siRNA) in 
exosomes with the use of the electroporation technique. Other studies also used this 
method for the incorporation of therapeutic cargo, with voltages in the range of 150-700 
V. Interestingly, the applied voltage for efficient exosome loading by electroporation may 
vary with the type of donor cell (immature dendritic cells, monocytes and HeLa cells, for 
example) [114,115].  
Electroporation may be a good option for exosome loading since it is easy to 
control the experimental parameters. However, some authors believe that it may induce 
adverse effects in the loaded cargo or in exosome integrity.  
For example, Kooijmanns et al. [111] showed that the process of electroporation can 
induce the formation of siRNA aggregates, and that only 0.05 % of the siRNA was 
successfully incorporated in exosomes using this method. Other work showed that 
electroporation can also induce the aggregation of exosomes themselves,; however, 
when the parameters are optimized, the aggregation can be significantly reduced, still 
allowing the incorporation of iron particles [110]. This method was also used for the 
incorporation of doxorubicin in targeted exosomes, showing that it can represent an 
efficient way to load chemotherapeutics in exosomes. Moreover, the drug was able to 
maintain its biological function [114].      
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Figure 14 – Scheme with the different strategies for exosome loading. Left side: Incorporation of the 
therapeutic cargo before exosome isolation. Transfection of cells with a vector encoding a protein and by 
simple exposure to a therapeutic molecule. Right side: Incorporation of the therapeutic cargo after exosome 
isolation. Electroporation, simple incubation, application of ultrasonic frequencies, repeated freeze-thaw 
cycles, treatment with detergent-like molecules, such as saponin, and extrusion. Figure adapted from 
reference [116]. 
 
1.5.1.2. Simple incubation 
 
   Simple incubation of the therapeutic cargo with exosomes is a common method 
for exosome loading. Only 5 minutes of incubation was needed to efficiently incorporate 
curcumin in exosomes at 22 ºC, and result in a significant anti-inflammatory effect in 
different disease models [117,118]. Curcumin can induce lipid rearrangement and 
changes in the membrane fluidity, and for this reason the incorporation of this molecule 
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in the exosome lumen is an easy process [119,120]. Some other therapeutic cargo was 
loaded in exosomes through incubation at 37 ºC for 1h and 2h, such as miR-150 and 
doxorubicin [121,122]. The relative small size of these molecules may be the reason for 
their successful incorporation in exosomes.   
 
1.5.1.3. Use of transfection agents 
 
    Commercial transfection agents can be used for the incorporation of a therapeutic 
cargo in exosomes. Normally, the cargo loaded in exosomes through this method is 
siRNA. There are at least two studies that used transfection reagents for the 
incorporation of siRNA in exosomes. They showed that the use of HiPerFect transfection 
reagent was less efficient than electroporation, and that the use of the very common 
Lipofectamine 2000 reagent resulted in the incorporation of siRNA in exosomes, 
decreasing gene expression after being delivered inside cells [115,123]. However, the 
effect of the loaded exosomes alone was not confirmed, because of the presence of 
captured siRNA in leftover micelles. So, the chemical-based transfection method does 
not seem adequate for the loading of therapeutic cargo, such as siRNA, in exosomes. 
 
1.5.1.4. Other methods 
 
Besides the methods already described, some other methods have been also 
used for the incorporation of therapeutic cargo in exosomes. For example, Haney et al. 
[124] tried to load the enzyme catalase in exosomes through different methods, such as 
saponin permeabilization, sonication, freeze-thaw cycles and extrusion. The most 
efficient methods were the sonication, saponin treatment and extrusion. Also in this 
study, the effect of these treatments in the morphology and size of exosomes was 
observed. Extrusion and sonication resulted in an increase of the exosome size as 
analysed by DLS, NTA and AFM. A similar study was performed by Fuhrmann et al. 
[125]. They observed an eleven-fold increase in the incorporation of porphyrins in 
exosomes through saponin permeabilization in comparison to simple incubation and 
extrusion. These methods for the incorporation of therapeutic cargo in exosomes are 
represented in Figure 14. 
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1.5.2. Exosome loading methods before EV isolation 
 
1.5.2.1. Cell exposure to the therapeutic cargo 
 
A possible method to load exosomes is by simply exposure of cells in culture to 
the therapeutic cargo. Pascucci et al. [126] showed the incorporation of Paclitaxel in EVs 
of mesenchymal stromal cells. This was accomplished by the exposure of MSCs to high 
dosages of Paclitaxel. Consequently, the cells produced EVs loaded with Paclitaxel that 
were able to inhibit in vitro tumour growth. 
 
1.5.2.2. Transfection of exosome producing cells 
 
Transfection of cells is probably the most used method for the incorporation of 
therapeutic cargo in exosomes. This is accomplished by transfection of exosome 
producing cells with a gene of interest that, when overexpressed, will give rise to the 
production of the protein of interest (therapeutic protein or gene product) which will then 
be incorporated in the lumen or membrane of exosomes [127,128]. For example, MSCs 
were transfected with a miR-46b vector, leading to the production of miR-146b-
expressing exosomes, which were then successful in the inhibition of tumour growth 
[128]. This study showed the capacity of using exosomes in cancer treatment. Also, 
another similar study demonstrated the production of exosomes with a targeting peptide 
that allowed  their targeted delivery after intravenous injection [127]. In the literature, one 
can also find reports on the use of cell transfection for overexpression and incorporation 
of a specific protein in  exosome membranes [129,130]. There are already commercial 
products for exosome engineering, like the incorporation of targeting peptides in the 
exosome membrane. The System Biosciences (SBI) company sells a product, called 
XStampTM, that makes use of a Lentivector for transfection and subsequent expression 
of a gene product incorporated in exosomes surface [131]. Figure 15 shows the vector 
used in this technology.  
However, one must keep in mind that cell engineering for production and 
presence of targeting peptides in exosomes surface, and incorporation of large amounts 
of cargo in their lumen, can be a laborious procedure. This can represent a problem in 
clinical applications, where patient cells are used for the production of engineered 
exosomes. Therefore, production of non-autologous exosomes with non-immunogenic 
properties would be of very great interest. 
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Figure 15 – XStampTM technology commercialized by System Biosciences company: (a) Lentivector with a 
ligand MCS for insertion of the gene of interest. (b) Representation of an exosome with the localization of 
the XStamp-ligand. (c) Scheme to produce XStamp-Motilin exosomes. Motilin is a 22-amino acid sequence 
polypeptide hormone that binds specifically to motilin receptor in the intestine cells. After being produced, 
the exosomes were added to the MDA-MB-231 breast cell line (motilin receptor negative) and HT-29 colon 
cancer cell line (motilin receptor positive). After 24 h, the cells were visualized in a fluorescence microscope, 
and the HT-29 cells took up the exosomes at much higher rate than the MDA-MB-231 cells. Figure adapted 
from reference [131]. 
 
 
1.6. Dendrimers as nanocarriers for drug delivery 
 
 “Dendrimer” comes from the Greek word dendron, which means “tree” and the 
word meros which means “part”. Dendrimer is a term internationally accepted, but other 
terms can be used, like “arborols” and “cascade molecules”. The first dendrimers were 
synthesized in the research group of Fritz Vögtle in 1978 [132]. After that, many different 
families of dendrimers were synthesized, like the poly(amidoamine) (PAMAM) dendrimer 
family that appeared in 1983 by the hands of Donald Tomalia [133,134]. PAMAM 
dendrimers are commercially available and are, by far, the most studied dendrimer 
family.  
 
1.6.1. Characteristics and molecular structure of PAMAM dendrimers 
 
Dendrimers are large and complex polymer molecules with a well-defined 
chemical structure. They possess three different architectural components: (i) an initiator 
(a) 
(b) 
(c) 
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core, consisting of a molecule with at least two identical chemical groups, (ii) interior 
layers (generations), composed of repeating units radially attached to the core, and (iii) 
many functional groups (multivalency), located in the surface of the dendrimers (Figure 
16). These surface groups are responsible for the important properties of dendritic 
macromolecules such as charge and solubility. When compared to other carrier systems, 
like linear polymers, dendritic structures have a huge potential because of their unique 
shape, nanoscale size and monodispersity [135].   
“Monodispersity” means that dendrimers possess a well-defined molecular 
structure. The monodispersity of dendrimers has been confirmed using techniques such 
as gel electrophoresis, mass spectrometry, size exclusion chromatography and 
transmission electron microscopy. Mass spectrometry analysis, for example, has shown, 
that PAMAM dendrimers (Figure 17) from generations 1 to 5, produced by the divergent 
method, are very monodisperse [136].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 – Representation of the general structure of dendrimers. Figure adapted from reference [132]. 
 
The size of dendrimers increases with the number of generations, from several 
to tens of nanometers in diameter. Dendrimers can have sizes resembling some 
biological structures - for example, generation 5 PAMAM dendrimer has a size (5.5 nm) 
and a shape similar to those of hemoglobin (Hb). Dendrimer size is also relevant for its 
three-dimensional shape. Lower generation dendrimers tend to have an open and 
amorphous structure, whereas the higher generations can adopt more spherical 
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conformations, being capable of incorporating guest molecules (like therapeutic 
compounds) within their branches [137].  
Like it was mentioned before, dendrimers are composed of three structural units: 
the core, the branching units and the terminal functional groups. These end groups may 
possess a negative, positive or neutral charge, which is fundamental in the exploration 
of these macromolecules as drug delivery carriers. This periphery charge can play an 
important role in dendrimer applications – for instance, cationic dendrimers such as 
PAMAM dendrimers with amino termini can be used for gene delivery purposes since 
they can form complexes with the anionic charged deoxyribonucleic acid (DNA) (Figure 
18). Also, the positive charge of dendrimers can facilitate the interaction with cell 
membranes, which are slightly negative due to surface glycoproteins, making them a 
suitable candidate for intracellular drug delivery. However, one problem associated with 
these positively charged dendrimers is the fact that they can induce some cytotoxicity, 
hemolysis, among others. Fortunately, this aspect can be overcome with dendrimer 
surface modification using different molecules, such as PEG, carbohydrates and acetate 
[138].         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 – Molecular structure of PAMAM dendrimers. Figure adapted from reference [138]. 
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1.6.2. Biomedical applications of PAMAM dendrimers 
 
The unique properties of dendrimers (nanometric size, tailor-made surface 
groups, extensive branching, excellent stability and monodispersity) have attracted the 
attention of researchers for their possible biomedical applications, such as nucleic acid 
delivery, controlled delivery of therapeutic compounds and use for imaging and 
diagnostic purposes.  
An extensive literature is available concerning the application of dendrimers in 
nucleic acid delivery, especially related with the use of amino terminated PAMAM 
dendrimers. The existence of amino groups at the dendrimer surface enhances nucleic 
acid transfection efficiency. Normally, the complexes formed by dendrimers and nucleic 
acids are called “dendriplexes”. Dendrimers showed good transfection efficiencies in the 
delivery of a variety of genetic materials, such as aptamers, antisense oligonucleotides, 
siRNA and genes [139]. The mechanism of nucleic acid delivery is represented in Figure 
18, specifically for the delivery of a gene. Briefly, the first step consists in the cellular 
uptake of the dendriplex by endocytosis, then followed by endosomal disruption and 
release of the complex into the cytosol. After, the DNA is disassembled from the 
dendrimer, it enters the nucleus and is replicated with the host DNA. After the 
transcription is accomplished, the product, mRNA, is released as a biosignal and 
translated into the protein of interest [140].                
 The intracellular delivery of a therapeutic cargo is one of the most promising 
applications of dendrimers. These macromolecules have been successfully used in 
different studies for intracellular delivery of diverse kinds of drugs which can be 
chemically conjugated to the dendrimers or just linked by physical means (like surface 
adsorption or encapsulation within dendrimer internal cavities) [138]. However, to 
achieve that purpose, it is necessary to prevent non-specific interactions between 
dendrimers and the systemic circulation, as well as a quick removal of the dendriplexes 
from the systemic compartment by renal clearance or phagocytosis by macrophages 
[138].  
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Figure 18 – Gene delivery mediated by dendrimers. Figure adapted from reference [132]. 
 
For example, conjugates of PAMAM dendrimers and methylprednisolone were 
rapidly internalized by human lung carcinoma epithelial cells [141]. The activity of the 
free drug was comparable to the one of the dendritic complex. Kolhe et al. demonstrated 
that ibuprofen covalently linked to PAMAM dendrimers was rapidly taken by A549 cells, 
and also that a sustained release of the drug was achieved. Indeed, dendrimers can be 
used for the successful intracellular delivery of therapeutic compounds and, also, as 
controlled drug delivery systems which will assure the release of the drug for a prolonged 
period [142]. 
 One last and important application of the dendrimers in the biomedical field is 
their application as imaging agents [143]. Nanomaterials based on dendrimers have 
been efficiently used as imaging agents in a diverse group of imaging techniques, like 
magnetic resonance imaging (MRI), computed tomography (CT) imaging, fluorescence 
imaging and positron-emission tomography (PET). For example, MRI is a non-invasive 
diagnostic technique, based in the different relaxation times of protons in different tissues 
that often uses gadolinium complexes as contrast agents. However, the Gd(III) ions are 
highly toxic due to their high affinity for serum proteins and are also quickly cleared from 
the systemic circulation limiting the time for medical analysis. To overcome this problem, 
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Gd(III) have been complexed to high molecular weight compounds, such as dextran, 
albumin, polylysine and dendrimers [144] . Dendrimers combined with gold nanoparticles 
may also find applicability as contrast agents in CT imaging to substitute the iodine 
compounds traditionally used that also raise problems of toxicity [143]. In fact, 
dendrimers can even be used as scaffolds for the construction of theranostics 
nanomaterials that can be applied for therapy and, simultaneously, for imaging purposes 
[143]. 
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1.7. Thesis objectives 
 
The main objective of this Master thesis was to evaluate the possibility of using 
exosomes derived from human mesenchymal stem cells (hMSCs) as carriers of 
dendrimers, more precisely generation 4 (G4) poly(amidoamine) dendrimers with amino 
termini (PAMAM(NH2)).  
Assuming the hypothesis that exosomes could be loaded before their isolation from 
cells by cell exposure to a dendrimer-containing solution, it was designed a set of 
experiments, in particular: 
a) The labelling of PAMAM dendrimers with rhodamine B isothiocyanate (RITC) and 
further characterization by Nuclear Magnetic Resonance (1H NMR), Fourier 
Transformed Infrared Spectroscopy (FTIR), UV/Vis spectroscopy, and 
fluorescence spectroscopy;  
b) the effect of the pH in the stability of the fluorescence emission of PAMAM(NH2)-
RITC conjugates; 
c) the cytotoxicity of the PAMAM(NH2)-RITC conjugates using cells in culture; 
d) the kinetics of PAMAM(NH2)-RITC conjugate cell uptake by fluorescence 
spectroscopy and fluorescence microscopy; 
e) establishment of an exosome isolation protocol using a precipitation-based 
approach and the physical and biochemical characterization of the isolated 
exosomes, for example, by Dynamic Light Scattering (DLS), detection of 
acetylcholinesterase (AChE) activity and Transmission Electron Microscopy 
(TEM); 
f) the exposure of hMSCs to PAMAM(NH2)-RITC conjugates and stimulation of 
exosome release; isolation of the exosomes and the confirmation of the presence 
of dendrimers in the exosome fraction by fluorescence spectroscopy; 
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2. Materials and methods 
 
2.1. Synthesis and characterization of PAMAM(NH2)-RITC conjugates 
 
2.1.1. Materials 
  
 Rhodamine B isothiocyanate (RITC, mixed isomers, BioReagent) was from 
Sigma-Aldrich. Generation 4 (G4) PAMAM dendrimers with ethylenediamine core, in 
methanol, with 100 % -NH2 end groups, were from Dendritech® (Midland, MI, USA). 
Dimethyl sulfoxide (DMSO, analytical grade) was from Fisher Scientific. The dialysis 
membranes were from SpectrumLabs (Spectra/Por ® 7 Dialysis Membrane with  
molecular weight cut-off (MWCO) of 6000-8000 Da). The ultra-pure (UP) water used in 
all experiments was obtained through a Millipore Milli-Q purification system with a 
resistivity higher than 18.2 MΩ.cm (at 25°C). 
 
2.1.2. Preparation and characterization of PAMAM(NH2)-RITC conjugates 
 
 For the preparation of PAMAM(NH2)-RITC conjugates, G4 PAMAM dendrimers 
with 100 % -NH2 surface groups were used. The synthesis conditions to obtain a specific 
number of RITC molecules attached to each dendrimer molecule were previously 
optimized and determined in our lab. The conditions for the conjugation are presented in 
Figure 19. To attach one molecule of RITC to one G4 PAMAM dendrimer (in average), 
RITC was used in excess (1.5 mol of RITC to 1 mol of dendrimer). As such, 33.7 mg of 
lyophilized dendrimer was firstly dissolved in 4.5 ml of DMSO. Then, the conjugation was 
started with the addition of 1.9 mg of RITC dissolved in 0.5 ml of DMSO. The reaction 
was performed for 18 h under stirring, in a dark environment, and at room temperature. 
After that, the solution was extensively dialysed against distilled water for 3 days. Then, 
the obtained purple solution was lyophilized, leaving 31 mg of conjugate.  
To assess the successful conjugation of RITC to the dendrimer, the conjugates 
and the non-conjugated PAMAM dendrimers and RITC molecules were characterized by 
different techniques, namely 1H NMR, UV/Vis, FTIR, and fluorescence spectroscopy. 
 For the 1H NMR characterization, a Bruker Avance II+ 400 MHz equipment at 25 
ºC (probe temperature) was used. The chemical shifts (δ) are presented in ppm and 
calibrated based on the residual solvent peaks. All the compounds were dissolved in 
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deuterated water (D2O). All NMR data was treated using the Mnova NMR ® software, 
v9.1.  
The UV/Vis spectra were obtained using a Perkin-Elmer Lambda 25 
spectrophotometer. All the measurements were done using a stopped quartz cell and for 
a scan interval between 190 and 900 nm. The conjugated and non-conjugated 
compounds were dissolved in UP water and analysed at the concentration of 1 µM.  
The FTIR spectra were obtained through an ATR coupled Perkin Elmer Spectrum 
Two spectrometer. The IR spectra were collected by pressing small amounts of the 
sample on a Diamond/ZnSe crystal. All the spectra were acquired at the resolution of 4 
cm-1, with a minimum number of 20 scans and along the spectral range of 4000 to 400 
cm-1. 
  
 
 
 
 
 
 
  
Figure 19 – Conjugation conditions for the preparation of G4 PAMAM(NH2)-RITC conjugates (1:1.5 
PAMAM:RITC molar ratio). 
 
2.1.3. Effect of the pH in the photostability of PAMAM(NH2)-RITC conjugates  
 
 To evaluate the photostability of the conjugates during the events of uptake and 
endosomal maturation, the fluorescence intensity of PAMAM(NH2)-RITC conjugates was 
measured at different pH values. 
Briefly, 100 µL of a 10 µM solution of the conjugates was dispersed at different 
pH values (3-10) in 4,9 ml of a buffer containing 31 mM C6H8O7 (citric acid), 29 mM 
KH2PO4 (monopotassium phosphate), 29 mM H3BO3 (boric acid) and 29 mM of 
C8H12N2O3 (diethylbarbituric acid). Then, 200 µL of each solution was transferred to an 
opaque 96 well plate, and the fluorescence intensity was measured with a microplate 
reader (Victor3 1420, PerkinElmer) at λex = 530 nm, λem = 590 nm.  
 (NH2)64 G4 
PAMAM(NH2) 
dendrimer in DMSO RITC in DMSO 
 G4 
1 
PAMAM(NH2)-RITC 
18h, RT 
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2.2. Cytotoxicity studies of PAMAM(NH2)-RITC conjugates 
 
 To determine the best concentration for the “in vitro” inclusion of the 
PAMAM(NH2)-RITC conjugates into the exosomes, as well as the concentration that 
would be the most suitable for cell uptake and colocalization studies, cytotoxicity assays 
were done. All the conditions applied for these studies are described in the next sections.  
 
2.2.1. Cell culture conditions for cytotoxicity analysis  
 
 All cytotoxicity assays were accomplished using human mesenchymal stem cells 
(hMSCs). The human mesenchymal stem cells were isolated from the bone marrow 
present in the trabecular bone of healthy adults which was obtained during surgical 
interventions after trauma. Only tissue that would have been discarded was used with 
the approval of the Ethical Local Committee (Hospital Dr. Nélio Mendonça, Funchal). 
First, primary hMSC cultures were established based on cells adherent to the plastic 
surface of the cell culture dish (VWR). Afterwards, cells were passaged using a standard 
protocol using trypsin (Gibco) and their number was expanded. Cells were always grown 
in 100 mm cell culture dishes using α-Minimum essential medium (α-MEM) (Gibco) 
supplemented with 1 % (v/v) of an antibiotic/antimycotic solution (AA, Gibco) and 10 % 
(v/v) of Fetal Bovine Serum (FBS, Gibco) - referred as “complete medium” from now on. 
The cells were cultured in an incubator (at 37ºC with 5 % CO2 atmosphere) until the 
desired number of cells were achieved and before reaching confluence.    
 
2.2.2. Effect on cell viability of PAMAM(NH2)-RITC conjugates 
 
 Non-conjugated generation 4 PAMAM dendrimers and PAMAM(NH2)-RITC 
conjugates were used in the cytotoxicity studies. 
 The cytotoxicity of these compounds was evaluated through the resazurin 
reduction assay. This assay relies on the assessment of metabolic active cells that can 
convert the non-fluorescent dye, resazurin, into a fluorescent product resorufin, which 
emits a fluorescence signal that can then be measured using a microplate reader. This 
assay assumes that there is a direct correlation between cell metabolic activity and the 
number of viable cells. As such, cell viability was determined as a percentage in relation 
to the non-exposed cells (control). For this purpose, the hMSCs were exposed to 
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different concentrations of compounds (1 – 0,1 µM). Cell viability was determined 24, 48 
and 72h of cell culture.  
 Briefly, the hMSCs were seeded in 48-well plates (VWR) at the density of 1 x 105 
cells per well with α-MEM complete medium, and left to incubate at 37 ºC in a 5 % CO2 
atmosphere. After 24 h, the medium was replaced with 450 µL of fresh one. Then, 50 µL 
of each dendrimer stock solution in UP water were added to each well to obtain the 
intended concentration.  
 After 24 h (exposure time), the cell culture medium was removed and complete, 
fresh, α-MEM medium containing 10 % (v/v) of a 0.1 mg/ml resazurin solution (Sigma-
Aldrich) was added to each well. The cells were then left to incubate for 4 h at 37 ºC and 
5 % CO2. After this time, 100 µL of the medium, from each well, were transferred to a 96 
opaque well-plate and fluorescence was measured using a microplate reader, at λex = 
530 nm, λem = 590 nm. Then, the wells were washed three times with PBS 1x (Sigma-
Aldrich), and 500 µL of α-MEM complete medium were added to each well. The same 
procedure was repeated after 48 and 72 h of culture. All the samples were analysed 
based on six replicates.       
 
2.3. Kinetics of cell uptake of PAMAM(NH2)-RITC conjugates 
 
 Having in mind the idea of loading exosomes with PAMAM(NH2)-RITC 
conjugates before their isolation from cells, the kinetics of cell uptake was studied. In 
these experiments, hMSCs were seeded at a density of 2x104 cells per well in a 24-well 
plate. Then, after 24 h, cells were exposed to 1 µM of conjugate (final concentration) in 
complete medium during different periods of time (6-30 h). Although this concentration 
resulted in some cellular toxicity, this value was selected in order to make the observable 
expected effects more evident. After that, medium was removed and the wells were 
washed 3 times with PBS 1x. Cells were then lysed with 100 µL of RIPA buffer (Amresco, 
VWR), supplemented with Protease inhibitor cocktail Set III, EDTA-free (Calbiochem, 
Merck Millipore) in the proportion of 1:200, and scrapped with a pipette tip. After this, 100 
µL of cellular suspension was transferred to an opaque 96-well plate, and fluorescence 
intensity was read in a microplate reader (Victor3 1420, PerkinElmer) at λex = 530 nm 
and λem = 590 nm. Cells under the same conditions were visualized in an inverted 
fluorescence microscope (Nikon Eclipse TE 2000-E). 
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2.4. Establishment of an exosome isolation protocol  
 
2.4.1. Definition of the protocol 
 
 For the establishment of an exosome isolation protocol, NIH 3T3 cells were used 
due to their easy maintenance and fast proliferation in culture. NIH 3T3 cells were 
cultured in Dulbecco’s modified eagle medium (DMEM) (Gibco), supplemented with 10 
% (v/v) FBS and 1 % (v/v) AA. Exosome-depleted FBS (Gibco) was always used when 
the objective was to harvest cell supernatants for exosome isolation. 
Isolation of exosomes from cell culture media was based on a precipitation-based 
approach using a commercial reagent, the Total Exosome Isolation Reagent (from cell 
culture media) from Invitrogen. This reagent makes less-soluble components, like 
exosomes, become insoluble, allowing their recovery by low-speed centrifugation. The 
guidelines recommended in the Total Exosome Isolation Reagent product sheet (see the 
annex) were generally followed, with adaptations. Briefly, when cells reached 70-80 % 
of confluence, cell culture medium was replaced with α-MEM supplemented with 10 % 
(v/v) of exosome-depleted FBS and 1 % (v/v) AA. Cells were incubated for 48 h, then 
the medium was harvested and submitted to differential centrifugation to remove cell 
debris and other types of extracellular vesicles. Cell culture medium was centrifuged at 
300 x g for 10 min to remove cell debris and the obtained supernatant was further 
centrifuged at 2 000 x g for 20 min to remove apoptotic bodies; again, the supernatant 
was centrifuged at 10 000 x g for 30 min to remove microvesicles. The supernatant was 
then mixed with half of its volume of Total Exosome Isolation Reagent and was incubated 
overnight at 4oC. The samples were then centrifuged at 10 000 x g for 1h at low 
temperature. The exosome-containing pellet was then resuspended in a phosphate 
buffered saline (PBS, Sigma) solution and, depending on the experiment, immediately 
analysed or stored at -80ºC.  
As exosomes are described in the literature as having a size below 200 nm [25], 
the introduction of a filtration purification step before addition of the commercial reagent 
to the exosome-containing medium was evaluated. For this, NIH 3T3 cells were used as 
exosome producers and the exosome-containing medium was filtrated using a 0.22 µm 
polyethersulfone filter (VWR). Also, since a big volume of supernatant was always 
harvested with a large amount of Total Exosome Isolation Reagent, the possibility of 
concentrating cell supernatants by exploring an ultrafiltration process was evaluated in 
order to not spend large quantities of the isolation reagent. Thus, the use of Amicon 15-
Ultra Centrifugal Filter Units 3 kDa MWCO (Millipore, Merck) was tested for supernatant 
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concentration after the mentioned filtration step. In these experiments, the presence of 
exosomes in the final solutions was assessed using the Dynamic Light Scattering (DLS) 
technique since it gives information regarding the hydrodynamic size of particles. A 
scheme of this study can be found in Figure 20. Samples were analysed immediately 
after exosome isolation. A control consisting of medium not exposed to cells was used. 
Overall, it was concluded that the filtration step did not have an impact on the quality of 
the DLS analysis whereas the concentration step improved it. Also, to diminish the 
expenditure with the Total Exosome Isolation Reagent, it was decided to keep the 
concentration step in the process of exosome isolation. 
After these preliminary experiments, the final protocol for isolation of exosomes 
was established which included an extra concentration step performed using Amicon 15-
Ultra Centrifugal Filter Units with 3 kDa MWCO (Millipore, Merck) in addition to the other 
procedures described in the second paragraph of this section,  
 
Figure 20 - Scheme for testing the influence of filtration and concentration steps in the isolation of exosomes. 
 
2.4.2. Effect of storage temperature on the stability of exosome solutions 
 
 The influence of the storage temperature in the stability of exosome solutions was 
also studied. For this, hMSCs were used to produce exosome-containing solutions. 
hMSCs cells were cultured in α-MEM (Gibco) supplemented with 10 % (v/v) FBS (Gibco) 
and 1 % (v/v) AA (Gibco). Only cells from passages 3 to 7 were used to obtain exosomes. 
Exosomes were isolated following the established protocol. After getting the exosome 
solutions, they were stored at different temperatures, namely 25oC (room temperature), 
4oC, -20oC and -80ºC for one week. Then, the hydrodynamic size of the particles in 
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ultrafiltration
/concentration
no concentration 
step
Non-filtered 
medium
3 kDa
ultrafiltration
/concentration
no concentration 
step
Part II  Materials and methods 
 
 
73 
solution was evaluated using the DLS technique to assess the quality of the exosome 
solutions. As a control, exosomes analysed immediately after exosome isolation were 
used.  
 
2.4.3. Exosome characterization 
 
2.4.3.1. Dynamic Light Scattering (DLS)  
 
 The hydrodynamic size of the isolated exosomes was analysed by a Malvern 
Zetasizer Nano ZS (Malvern, UK). For this purpose, exosome solutions stored at -80 ºC 
were thawed, diluted in PBS 1x at different concentrations and then analysed at 25 ºC 
with a measurement angle of 173º. All the experimental conditions were maintained 
constant in all the measurements.  
 
2.4.3.2. Transmission Electron Microscopy (TEM) 
 
Exosomes were prepared and visualized in an analytical TEM Hitachi 8100, 
equipped with a ThermoNoran light elements EDS detector and digital image acquisition. 
Preparation of the samples was assessed as described previously by Lötvall et al. [145]. 
The exosome solutions were thawed from -80 ºC and drops were placed in Parafilm film. 
Then, with the help of a forceps, a formvar carbon coated nickel grid was placed on the 
top of each drop for 30-60 min. After this, each grid was washed thrice with 30 µL of PBS 
1x. Samples were then fixed in a drop of 2 % paraformaldehyde (Sigma) for 10 min and 
washed thrice with 30 µL of PBS 1x. Samples were contrasted by adding a drop of 2 % 
uranyl acetate for 10 min. Excess liquid was removed by gently using absorbing paper, 
and the grids were air dried for 5 min before analysis. 
 
2.4.3.3. Acetylcholinesterase (AChE) activity  
 
To verify and validate the presence of exosomes in solution, the activity of 
acetylcholinesterase was measured. AChE is an enzyme that is specific to these vesicles 
[146]. The acetylcholinesterase activity was assessed as previously described by Savina 
et al. [147]. Briefly, 40 µL of exosome suspension was diluted in 110 µL of PBS 1x. Then, 
37.5 µL of this diluted suspension was added to a transparent 96-well microplate. Then, 
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1.25 mM of acetylthiocholine iodide (Sigma Aldrich, Merck) and 0.1 mM of 5,5’-
dithiobis(2-nitrobenzoic acid) (Sigma Aldrich, Merck) were added to each well to a final 
volume of 300 µL, and incubated at 37 ºC. The change in absorbance at 412 nm was 
read each 5 min for 30 min. The control contained complete medium supplemented with 
10 % (v/v) exosome-depleted FBS and 1 % (v/v) AA. All the measurements were done 
in triplicate. 
 
2.5. Exosome loading with PAMAM(NH2)-RITC conjugates 
 
 In this thesis, it was hypothesized that exosomes could be loaded with 
PAMAM(NH2)-RITC conjugates before their isolation from cells, a technique described 
in the literature as being successful for other cargo [26]. Briefly, the hMSCs were seeded 
in 100 mm Petri dishes. After attaining 70-80 % of cell confluency, the medium was 
replaced by fresh medium with 1 µM of conjugates (final concentration) and exposed for 
24h (exposition time to conjugates). Then, cells were washed with PBS and cultured 
during two more days. After this period, the medium was collected and exosomes were 
isolated according to the protocol previously established. 
Since there is also the possibility that the conjugates are integrated into 
microvesicles, a parallel study was performed where microvesicle release was 
stimulated by culturing cells in FBS-free medium for 2 days after 24h exposition time to 
conjugates (this will be referred as the “activation step”). It is reported that a serum-
depleted medium induces cell stress, which can increase the release of microvesicles 
[140]. In this case, the microvesicle fraction was collected by differential centrifugation 
and analysed.  
Both microvesicles and exosome pellets were resuspended in PBS.  After, 100 
µL of each suspension were transferred to an opaque 96-well plate, and fluorescence 
intensity was measured in a microplate reader. Also, an aliquot of the microvesicles 
suspension was placed on microscope slides and observed under an inverted 
fluorescence microscope; the same was not done for exosomes since the optical 
microscope does not have enough resolution for their observation. In these studies, 
control experiments were done with PAMAM(NH2)-RITC non-exposed cells.      
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2.6.  Intracellular distribution of PAMAM(NH2)-RITC conjugates 
 
 Since the presence of PAMAM(NH2)-RITC conjugates was not detected in 
microvesicles and exosomes, the fate of the conjugates inside cells was investigated 
using fluorescence microscopy. In these experiments, besides hMSCs, MCF-7 cells 
were also used due to their easy maintenance and fast proliferation in culture. hMSCs 
cells were cultured as mentioned before and MCF-7 cells were cultured in RPMI (Gibco), 
supplemented with 10 % (v/v) FBS (Gibco), 1 % (v/v) NEAA (non-essential amino acids, 
Gibco), 1mM of pyruvic acid (Sigma-Aldrich), 10 µg/ml of human insulin (Sigma-Aldrich) 
and 1 % (v/v) AA (Gibco).  
First, hMSCs and MCF-7 cells were seeded at a density of 2x104 cells per well in 
a 24-well plate. Then, cells were exposed to 1 µM of conjugates for 24 h in complete 
medium. After incubation with the conjugates, cells were labelled with specific cell 
organelle fluorescent probes (Invitrogen, ThermoFisher). To label the endoplasmic 
reticulum, cells were washed three times with PBS 1x and then incubated with 2 µL of 
CellLightTM ER-GFP, BacMam 2.0 (green fluorescence colour) in complete medium, 
overnight, at 37ºC. To label the Golgi complex, cells were washed three times with PBS 
1x, fixed with 4 % of paraformaldehyde and permeabilized with 0.2 % of Triton X-100. 
Then, cells were incubated with 50 µg/ml of Lectin HPA (green fluorescence colour) in 
complete medium for 45 min. To label actin (microtubules), the same procedure as the 
Golgi complex staining was followed, but in the end, Alexa Fluor 488TM Phalloidin stain 
was added and left to incubate for 30 min. All the cells were counterstained with the 
nuclear stain DAPI (blue fluorescence colour) (Sigma-Aldrich, Merck). Briefly, a 1:2500 
solution of DAPI in PBS 1x was prepared from an existent stock solution (5 mg/ml in PBS 
1x). Then, a volume of diluted DAPI solution sufficient to cover the cells was added to 
the wells and left for 15 min at room temperature. After this, cells were washed three 
times with PBS 1x and visualized under an inverted fluorescence microscope (Nikon 
Eclipse TE 2000-E).  
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3. Results and discussion 
 
3.1. Synthesis and characterization of PAMAM(NH2)-RITC conjugates 
 
 Since the main objective of this Master thesis was to evaluate the possibility of 
using exosomes derived from human mesenchymal stem cells (hMSCs) as carriers for 
dendrimers, the first experimental step was to label them with a fluorescence probe. As 
such, generation 4 (G4) poly(amidoamine) dendrimers with amino termini 
(PAMAM(NH2)) were reacted with rhodamine B isothiocyanate (RITC) to get 
PAMAM(NH2)-RITC conjugates.  The reaction is between the isothiocyanate group in 
RITC and a primary amine (acting as a nucleophile) at the surface of a PAMAM 
dendrimer, resulting in a thiourea bond. There are many reports in the literature regarding 
this type of reaction between primary amines and isothiocyanate groups. In fact, a lot of 
dyes have been attached to proteins through this kind of reaction, because these dyes 
are rich in primary amines [148]. Moreover, several works mention the functionalization 
of PAMAM dendrimers with the fluorescein isothiocyanate (FITC) dye that also has an 
isothiocyanate group which can directly form a thiourea bond with the primary amines of 
the dendrimer [149–151]. One should keep in mind that, normally, this kind of reaction is 
highly selective for primary amines [152].  
As show in Figure 21, this reaction begins with a nucleophilic attack of the amine 
to the electrophilic carbon of the RITC isothiocyanate group. This reaction leads to an 
electron shift that results in the formation of a thiourea bond between the RITC and the 
PAMAM dendrimer. It has been reported that the conjugation between primary amines 
and isocyanate groups takes about 18 h [153].    
Thiourea bonds have a limited stability due to hydrolytic events that may occur, 
specially at room temperature [154]. So, these conjugates were maintained at a low 
temperature (4ºC) to reduce hydrolytic events and consequently increase the lifespan of 
the conjugates.      
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Figure 21 – Representation of the reaction between the primary amines in the PAMAM dendrimer and the 
electrophilic carbon of the RITC isothiocyanate group. 
 
 It is important to keep in mind that one should functionalize the surface of 
dendrimers with the minimum number of fluorescent molecules for diverse reasons. One 
of the most important reasons is that an extensive functionalization of the nanomaterial 
would result in a different dendrimer surface, consequently leading to a different 
biological response. Other important aspect, is that the higher degree of functionalization 
could result in self-quenching effects due to spatial proximity between fluorescent 
molecules [155]. So, in this work, the reaction was done to obtain only one molecule of 
RITC per dendrimer (in average). Previous work done in our group showed that to obtain 
this result the reaction should be done at a PAMAM dendrimer:RITC molar ratio of 1:1.5. 
 The success of labeling of the PAMAM(NH2) G4 dendrimer with RITC was 
assessed through different techniques, such as Nuclear Magnetic Resonance (1H NMR), 
Fourier Transformed Infrared Spectroscopy (FTIR), UV/Vis spectroscopy, and 
fluorescence spectroscopy. The 1H NMR spectrum of the PAMAM(NH2)-RITC 
conjugates is shown in Figure 22. There, one can see the characteristic peaks of 
PAMAM(NH2) G4 around δ=3.5 - 2 ppm, identified with the letter a. Also, one can confirm 
the successful conjugation of the RITC molecule to the dendrimer by the appearance of 
a new peak around δ=6.96 ppm. Like it was demonstrated in previous studies [156], this 
peak is characteristic of the formed thiourea bond, and is identified in Figure 22 with the 
letter b. It should be referred that the visualization of the peaks characteristic of the RITC 
is very difficult, due to the large difference in the number of protons between the 
dendrimer and the RITC molecule. For comparative effects, the 1H NMR of both the non-
conjugated dendrimer and RITC molecule are presented in the Annexes Section A. The 
conjugation of 1 molecule of PAMAM dendrimer to 1 molecule of RITC was confirmed 
by calculating the ratio between signal integrals.       
 
PAMAM PAMAM 
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Figure 22 – The 1H NMR spectrum of the PAMAM(NH2)-RITC conjugate in D2O (400 MHz). a: PAMAM(NH2) 
G4 dendrimer; b: thiourea; c: RITC; d: urea. 
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 To confirm the success of conjugation, the compounds were analysed with other 
spectroscopic techniques. In Figure 23, the FTIR-ATR spectrum for the PAMAM(NH2)-
RITC conjugate is shown. The appearance of bands around 1100-1300 cm-1 are 
probably associated with the stretching of the formed thiourea bond [157].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 – FTIR-ATR spectra of (a) RITC molecule, (b) PAMAM(NH2) G4 dendrimer and (c) PAMAM(NH2)-
RITC conjugate. 
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However, the existence of a weak broad peak around 2100 cm-1, characteristic of the 
stretching of the isothiocyanate group, points out that some non-conjugated RITC 
molecules can be associated with the dendrimers by physical interactions and not by 
chemical means. 
Figures 24 and 25 show the UV/Vis (absorption) and fluorescence emission 
spectra of the prepared PAMAM(NH2)-RITC conjugate, respectively. The analysis of the 
UV/Vis (absorption) spectrum of the conjugate shows a band of absorption with a 
maximum at 560 nm that can only be attributed to the presence of the rhodamine label. 
A slight bathochromic shift (red shift) in the wavelength of maximum absorption could be 
observed for the conjugate (560 nm) in relation to free RITC (558 nm). This behaviour is 
also described in the literature for other kinds of materials labelled with RITC, like 
microspheres [97,158]. As expected and in agreement with previous data, the emission 
spectrum of the PAMAM(NH2)-RITC conjugate shows two bands of emission at 
wavelengths close to those shown by free RITC. Also, there is a slight red shift in the 
wavelength of maximum emission when RITC is conjugated to the dendrimer. 
 
 
 
 
 
 
 
 
 
Figure 24 - UV/Vis spectra for the PAMAM(NH2)-RITC conjugate and the free RITC. Both compounds 
were analysed at a concentration of 1 µM.  
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Figure 25 – Emission spectra for the PAMAM(NH2)-RITC conjugate and the free RITC. Both compounds 
were analysed at a concentration of 1 µM.  
 
3.2. Effect of the pH in the fluorescence intensity of PAMAM(NH2)-RITC conjugates 
 
 The labelling of nanomaterials with different fluorescent probes is a widely 
employed method to study the efficiency of their cellular internalization and the 
localization of these nanomaterials once inside cells. According to literature, 
nanomaterials can follow different endocytic routes during cell uptake involving a set of 
vesicle maturation and acidification events (Figure 26). The pH inside these vesicles can 
go from 6.2 - 6.5 in early endosomes to 4.5 - 6 in late endosomes and lysosomes [159]. 
Since the present work also involves the tracking of PAMAM(NH2)-RITC conjugates 
inside cells, it was decided to evaluate the effect of pH on their fluorescence intensity.  
 
 
 
 
 
 
Figure 26 – Normal acidification of endosomes during their maturation to late endosomes and lysosomes. 
This occurs via transport of H+ ions across the endosomal membrane by V-type ATPases, which produces 
an electrical gradient that is balanced by the influx of counter-ions, like Cl- ions. Figure adapted from 
reference [160]. 
583.5 nm 
581.5 nm 
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Rhodamine dyes are fluorophores from the xanthene’s family, along with 
fluorescein and eosin. In acidic conditions, the rhodamine dyes are found in their cationic 
form due to the protonation of the carboxylic groups. At neutral pH, the carboxylic groups 
are deprotonated, and because of the positively charged nitrogen in the alkyl arms, these 
dyes are found in the zwitterionic form, as shown in Figure 27. Under alkaline conditions, 
the zwitterionic form undergoes  a reversible conformation to a lactone, which results in 
the interruption of the π-conjugation of the fluorophore [161]. Consequently, absorption 
of this lactones occur in the UV, and the quantum yield and lifetime are very low 
[162,163].  
 
 
 
 
Figure 27 – Molecular structures of the three Rhodamine B forms. Image adapted from reference [161]. 
 
 Figure 28 shows the impact of a range of pH values (3 – 10) on the fluorescence 
intensity of the conjugates. Through the analysis of this graphic, one can see that the 
fluorescence intensity is relatively stable in the pH range 3 – 7 and only starts to decrease 
at higher pHs (8 – 10). Considering what was mentioned before, this was the expected 
behaviour since rhodamine dyes have a higher fluorescence signal when they are in their 
cationic and zwitterionic forms present at acidic and neutral pH, respectively. Lee et al. 
[164] reported that RITC-incorporated silica oxide nanoparticles also showed a very 
stable fluorescence intensity behaviour under acidic conditions, without dissociation of 
RITC from the nanoparticles, and without any relevant changes in their size and surface 
charge. So, the present results reveal that the option to use RITC as a label for 
dendrimers was adequate, being a good fluorophore to track the conjugates upon their 
internalization in cells.  
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Figure 28 – Effect of pH change on the fluorescence intensity of the prepared PAMAM(NH2)-RITC 
conjugates. The fluorescence intensity is presented as relative fluorescence units (RFU). 
 
3.3. Cytotoxicity studies of PAMAM(NH2)-RITC conjugates 
 
 Figures 29 and 30 show the cytotoxicity over hMSCs of non-conjugated and 
conjugated PAMAM dendrimers, respectively, as a function of concentration and time 
after an initial exposure period of 24 h. Results are presented as a percentage of cell 
viability in relation to the control (cells not exposed to the free dendrimers or conjugates). 
Cell viability was correlated with the metabolic activity of cells since the resazurin 
reduction assay was used. This method assumes that healthy metabolic active cells can 
convert the non-fluorescent resazurin molecule in a fluorescent product, resorufin, 
whereas non-viable cells cannot. Because both dyes are membrane-permeable, the 
resazurin can enter the cells and be reduced, while the product of this reduction, 
resorufin, can leave the cell through the plasma membrane and accumulate in the cell 
medium. So, after exposing the cells to free dendrimers or conjugates, the resazurin 
reagent was added to the cells, and left to incubate for a certain time. After, the 
fluorescence signal coming from the medium was measured using a microplate reader 
[165,166].   
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Figure 29– Cytotoxic behaviour of generation 4 PAMAM(NH2) dendrimers over hMSCs. Each data set was 
plotted based on the mean and the corresponding relative standard deviation (RSD) of a single independent 
study with six replicates for each concentration. 
 
 
 
 
 
 
 
   
 
 
Figure 30 – Cytotoxic behaviour of PAMAM(NH2)-RITC conjugates over hMSCs. Each data set was plotted 
based on the mean and the corresponding RSD of a single independent study with six replicates for each 
concentration. 
 
 Analysing figures 29 and 30, one can see that cytotoxicity increased with 
concentration and time after an initial exposure period of 24 h. Interestingly, there was a 
difference between the cytotoxic behaviour of the non-conjugated and conjugated 
PAMAM dendrimers. For all the concentrations tested, the non-conjugated dendrimer 
showed a much higher degree of cytotoxicity when compared to the dendrimer 
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conjugates. This may be due to dendrimer’s amine termini that are protonated at 
physiological pH, leading to a strong positive charge in the molecule. The cells have 
negatively charged membranes, and when they are exposed to strongly positive 
molecules, such as cationic dendrimers, the difference in charge contributes for 
membrane destabilization, and consequently, to a higher cytotoxicity [167,168]. There 
are many reports in the literature highlighting the cytotoxicity behaviour of cationic 
PAMAM dendrimers and, also, referring different methodologies for decreasing their 
cytotoxicity. One possibility is to functionalize the dendrimer’s surface and mask the 
positive charges [138]. For example, it has been reported that dendrimer’s surface 
modification with polyethylenoglycol (PEG) chains results in a dramatic decrease of 
cytotoxicity [169]. Therefore, one can postulate that the presence of rhodamine at the 
dendrimer’s surface acts in a similar way, reducing the dendrimer charge.  
 Based on these results, a concentration of 1 µM of conjugated dendrimer was 
used in the following studies, namely for the experiments related with the kinetics of 
cellular uptake, exosome loading and localization of conjugates inside cells.  Indeed, this 
concentration was enough to give high fluorescence signals after the internalization of 
conjugates by cells without significantly affecting cell viability (higher than 60 % after 
24h).  
 
3.4. Kinetics of cell uptake of PAMAM(NH2)-RITC conjugates 
  
The intracellular components are protected from the external environment by the 
cytoplasmic membrane. The cell membrane is responsible for diverse important 
functions, such as cell homeostasis, ion concentration gradients, structural support, cell 
communication with the environment and entry/exit of nutrients and small molecules 
[170,171].  In nanomedicine, most of the nanomaterials must exert their therapeutic 
effect inside cells. However, the entry of nanoparticles in the cells remains a major 
challenge. Also, a more comprehensive understanding of nanoparticles uptake 
mechanisms is necessary for a better modulation of their physicochemical properties in 
order to achieve a higher efficiency and safety [172]. 
 Before nanomaterials reach the cell membrane, they must first interact with the 
extracellular environment, like fibrosis, pH, extracellular matrix, and so on. This 
environment can induce some changes in the properties of nanomaterials. For instance, 
this interaction normally leads to the absorption of proteins in the surface of nanoparticles 
(the protein corona) affecting their interaction with the cytoplasmic membrane and 
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subsequently their intracellular distribution [173]. The capacity of nanoparticles to adhere 
and cross cell membranes is related to their physicochemical properties, such as size, 
charge and surface composition. Small and positive charged molecules, such as 
dendrimers with amine termini, are capable of crossing the cell membrane, where 
sometimes they can lead to membrane disruption and induce some cytotoxic effects 
[174].       
 As the main hypothesis of this thesis was to load exosomes with PAMAM(NH2)-
RITC conjugates before their isolation from cells, the kinetics of their cell uptake was 
studied. Cells were exposed to the conjugates at different times (6, 16, 24 and 30 h) and 
then lysed in a buffer to release their content. The fluorescence intensity due to conjugate 
internalization in cells was then measured using a microplate reader. The results are 
shown in Figure 31.  In order to elucidate how dendrimers can increase the uptake of 
drugs, Goldberg et al  [175] showed that PAMAM G3.5-SN38 conjugates can enter Caco-
2 cells more easily than free SN38, which showed only 5 % of the conjugates uptake.  
Therefore, one can see that with an increase of the exposure time, there is also an 
increase in the fluorescence signal, reaching a maximum at 24h. So, 24h of cell exposure 
to the PAMAM(NH2)-RITC conjugates should be sufficient to apply in the exosome 
loading process.  
 
 
 
 
 
 
 
 
 
 
Figure 31 – Kinetics of cell uptake of PAMAM(NH2)-RITC. hMSCs were exposed to conjugates during 
different times (6, 16, 24 and 30h). The fluorescence intensity is presented as relative fluorescence units 
(RFU). 
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Fluorescence microscopy was also used to follow the kinetics of conjugate cell 
uptake (Figure 32). First, using the bright field mode in the microscope, one could 
observe that cells had a healthy aspect, even after 72h of exposure to conjugates, which 
confirms that the conjugate concentration used was tolerable by cells. When using the 
fluorescence mode in the microscope, and in agreement with the quantitative results, 
one could see an increase with time of the red fluorescence signal coming from the 
internalized conjugates. Again, fluorescence intensity tended to stabilize after 24h of cell 
exposure to PAMAM(NH2)-RITC conjugates.  Curiously, as time passed, one noticed 
that the fluorescence signals seemed to be more concentrated in the cell perinuclear 
zone.   
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Figure 32 – Fluorescence microscopy images of hMSCs exposed to PAMAM(NH2)-RITC conjugates during 
different times: a-30 min; b-1h; c-1h:30min; d-2h; e-3h; f-4h; g-5h; h-6h; i-7h; j-8h; k-12h; l-24h;  m-48h; n-
72h. All the images were taken with a magnification of 200 x.  
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3.5. Establishment of an exosome isolation protocol and exosome 
characterization 
 
The advances in the understanding of the biological functions of exosomes have 
been unveiling the contribution  of these vesicles  for the physiological maintenance of 
the human body [176]. Consequently, the isolation of exosomes became a major area of 
interest, both in the field of research and clinical applications. Exosomes must be isolated 
in a reliably manner from diverse kinds of biofluids, like blood, urine and cerebrospinal 
fluid. As described in the introduction of this thesis in more detail, there are different 
techniques used for the isolation of exosomes, like ultracentrifugation, precipitation, 
immunoaffinity, microfluidics, among others. This thesis assumed as an initial hypothesis 
that exosomes could be loaded with the PAMAM(NH2)-RITC conjugates before their 
isolation from cells by cell exposure to a solution containing these compounds. The cells 
would then excrete the exosomes into the cell culture medium.  As such, a protocol to 
isolate exosomes from the cell culture medium had to be developed before further 
studies.  
In this work and due to limitations of available equipment, a precipitation 
approach with a commercial reagent (Total Exosome Isolation Reagent, from cell culture 
media) was used for the isolation of exosomes. Typically, these commercial reagents 
contain a polymer that interferes with the solvent molecules (water in this case), thus 
forcing the less soluble components, like exosomes, to precipitate. The advantage of this 
method is that there is no need to use an ultracentrifuge to obtain the exosomes. 
The guidelines for using the Total Exosome Isolation Reagent (see annex D), 
only include one centrifugation step before the use of the Total Exosome Isolation 
Reagent to obtain a pellet rich in exosomes: cell media is centrifuged at 2000 × g for 30 
minutes to remove cells and debris. So, using this methodology, further purification steps 
(for example by affinity methods) would be required to get relatively pure exosomes. 
Having this is mind, it was decided to previously submit the cell culture media containing 
exosomes to a differential centrifugation process. That is, cell culture media was 
subjected to a series of centrifugation steps with increasing g forces and increasing 
centrifugation times: 300 x g for 10 min to remove cell debris; 2000 x g for 20 min to 
remove apoptotic bodies; and 10000 x g for 30 min to remove microvesicles. During 
these centrifugation steps, exosomes were always present in the supernatants. At the 
end, the last supernatant collected (already rich in exosomes) had to be mixed with half 
of its volume of Total Exosome Isolation Reagent.  
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In order to improve the exosome isolation protocol, the introduction of two other 
steps before addition of the commercial reagent to the exosome-containing medium was 
tested: (a) an early purification step (a filtration process using a 0.22 µm filter since 
exosomes have a size below 200 nm); (b) a concentration step (an ultrafiltration process 
using Centrifugal Filter Units with MWCO of 3 kDa in order to avoid the use of a large 
volume of Total Exosome Isolation Reagent,).  In these experiments, NIH 3T3 cells were 
used for practical reasons related with their easy maintenance and fast proliferation in 
culture. The presence of exosomes in the final solutions was assessed using the 
Dynamic Light Scattering (DLS) technique since it gives information regarding the 
hydrodynamic size of particles. Results of these experiments are summarized in Figure 
33 where the graphics show the hydrodynamic size distribution by intensity. The four 
plots in this figure always reveal the presence in the final solution of two families of 
particles having two distinct hydrodynamic diameters, represented by two peaks always 
clearly seen in the plots). Peak 1 can be attributed to the presence of the polymer in the 
Total Exosome Isolation Reagent together with other macromolecules from FBS 
(probably aggregates) or even small cell debris. Only the presence of the polymer cannot 
explain peak 1 since the analysis by DLS of the Total Exosome Isolation Reagent alone 
gives a peak around 3 nm (data in annex C). Peak 2 values are compatible with the 
characteristic size of exosomes. It is important to remember that, normally, exosome 
suspensions are very heterogenous in size, ranging from 50 to 150 nm [116]. 
Nevertheless, there are some studies, where the obtained exosome suspensions 
presented z-average values of 170 nm [55]. 
According to Figure 33, samples processed without the initial filtration and 
concentration steps presented the higher hydrodynamic diameter values and, also, the 
higher polydispersion index (PdI= 0.427). The introduction of a concentration step had 
an impact on the PdI value (PdI= 0.281) and resulted in smaller hydrodynamic diameter 
values. In case of samples processed with an initial filtration step, the concentration step 
also resulted in a diminishment of the polydispersion index (from PdI= 0.316 to 
PdI=0.214) and the measured hydrodynamic diameters. It seems, therefore, that DLS 
measurements in the more concentrated samples are more precise. For this reason, it 
was considered that a filtration step was not essential for the overall process of exosome 
isolation, whereas a concentration step would provide DLS measurements with higher 
quality. In addition, the concentration step has advantages as it is not necessary to use 
a larger volume of Total Exosome Isolation Reagent.
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A protocol to isolate exosomes from cell culture medium was then established 
that included a concentration step, which is schematized in Figure 34.  
 
 
 
 
 
 
 
 
 
 
Figure 34 – Schematized protocol of the established exosome isolation protocol. 
 
The influence of the storage temperature in the stability of exosome solutions was 
also evaluated. For this, hMSCs were used to produce exosome-containing solutions 
and exosomes were isolated following the previously established protocol. After 
obtainment of the exosome solutions, they were stored at different temperatures, namely 
25oC (room temperature), 4oC, -20oC and -80ºC for one week. Then, the hydrodynamic 
size of the particles in solution was once again evaluated using the DLS technique to 
assess the quality of the exosome solutions (Figure 35). As a control, exosomes 
analysed immediately after their isolation were used. Overall, the results demonstrated 
that exosomes can be stored for one week without relative changes in size even at room 
temperature. However, for longer periods of storage, it is obvious that they should be 
kept at -20/-80 ºC to prevent protein denaturation and microbial development.      
Human mesenchymal stem cells present a high proliferative and 
immunosuppressive capacity, which makes them the ideal candidates for mass 
production of exosomes [90]. Since the aim of this thesis was to try to use exosomes 
from hMSCs as carriers for dendrimers, after establishing a protocol for exosome 
isolation, exosomes from hMSCs were isolated and characterized by DLS, TEM and 
detection of a biochemical marker, namely the acetylcholinesterase (AChE) enzyme. 
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Characterization of exosomes is important to confirm their presence at the end of the 
isolation process. 
 
 
 
 
 
 
 
 
 
 
Figure 35 – Effect of storage temperature in the hydrodynamic size (Z-average) of the exosome solutions. 
Samples were analysed after being stored for 1 week. 
 
Figure 36 represents the DLS analysis showing the hydrodynamic size 
distribution (by intensity) of the exosome solution isolated from hMSCs culture medium. 
Like it was seen for exosomes derived from NIH 3T3 cells, two populations of particles 
are evident in the plot: one with a peak around 25 nm (again this can be attributed to the 
presence of the reagent polymer together with other macromolecules from FBS or even 
small cell debris); and another one with a peak around 200 nm that should correspond 
to exosomes. It must be noticed that a relatively high PdI (0.563) was associated with 
this analysis, possibly revealing a higher heterogeneity nature of hMSCs exosomes 
when compared with NIH 3T3 exosomes. 
  
 
 
 
 
 
 
Figure 36 – Characterization of exosomes derived from hMSCs by DLS. The graphic shows the 
hydrodynamic size distribution by intensity. 
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 Figure 37 is a micrograph from the exosome solution obtained by TEM analysis. 
The sample was stained with uranyl acetate that corresponds to the darker areas in the 
image. White circular spots, with and average diameter of 30-50 nm, can be seen and 
possibly correspond to exosomes due to their spherical morphology and size. They 
present a small size in comparison to the values determined by DLS since here they are 
in a dry state, whereas the size in DLS refers to their hydrodynamic diameter. Also, and 
like it was mentioned before, exosome suspensions are very heterogenous, and the 
image only represents a small observation field of the grid. Probably, if the grid was 
intensely analysed, other exosomes with different sizes would be found. Several reports 
in the literature show exosome images obtained using TEM where the size of these 
structures is around 50 nm or even less as exosomes tend to collapse upon drying [177]. 
The small white points in the image should correspond to the reagent polymer together 
with other macromolecules from FBS or small cell debris. 
 
 
 
 
 
 
 
 
 
 
Figure 37 – Transmission electron microscopy image of a negative stained hMSCs exosome solution. The 
arrows point to white circular cup-shaped vesicles, exosomes.  
 
 Exosome presence was also validated by measuring the activity of 
acetylcholinesterase, according to the method of Savina et al [146]. AChE is an enzyme 
specific to exosomes [178] and, by analysis of Figure 38, one can see that AChE activity 
was much higher when analysing the exosome solution than in the control solution.  
 In conclusion, taken together, the exosome characterization results point out that 
the protocol established for exosome isolation was successful, independently of the cell 
source used.  
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Figure 38 – Acetylcholinesterase assay of the exosome suspension obtained from hMSCs cells cell 
culture medium. Control used was based in the isolation from cell culture medium with no cells.  
 
3.6. Exosome loading with PAMAM(NH2)-RITC conjugates  
 
 After confirming that the PAMAM(NH2)-RITC conjugates could be internalized by 
cells and after designing a successful protocol for recovering exosomes from cell culture 
medium, the following step was to try to obtain exosomes loaded with the conjugates 
only by subjecting hMSCs to their presence – that is, to load exosomes before their 
isolation from cells.  As such, cells were exposed to PAMAM(NH2)-RITC conjugates for 
24h, washed with PBS and then cultured for more 48h. Next, the exosomes were 
isolated, lysed and fluorescence intensity was measured to check the presence of the 
conjugates. Simultaneously, as the conjugates could also be released inside 
microvesicles, an additional study was performed where cells passed through a process 
of activation to increase the production of microvesicles. For this, the microvesicle 
fraction was collected by differential centrifugation and analysed following the same 
methodology used for exosomes. In opposition to what was expected, the fluorescence 
intensity in all measured samples was close to zero, meaning that the conjugates were 
not present inside exosomes or microvesicles. Observation of microvesicles by 
fluorescence microscopy confirmed this finding (Figure 39). 
   
 
 
 Bright Field Red Filter Merged 
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Figure 39 – Fluorescence microscopy images of the PAMAM(NH2)-RITC conjugates inside microvesicles. 
These images are only of the microvesicles, because exosomes are not detectable with this kind of 
microscopy.   
 
To elucidate the reason why the conjugates were retained inside the cell, it is 
crucial to understand some aspects regarding the intracellular trafficking of 
nanomaterials, and how they can affect their excretion by cells. According to Panyam et 
al. [179], there are two possible recycling processes for nanomaterials, one by the 
endosomes and other by the lysosomes/cytoplasm. So, after endocytosis, one part of 
the nanoparticles is delivered to the lysosomes or translocated from the endosomes to 
the cytoplasm, whereas the other part remains inside the endosomes or is recycled back 
to the cell surface (see Figure 40). As for the exocytosis of nanoparticles, it seems that 
at least two intracellular compartments are involved, one with a fast turnover and another 
one with a slow turnover. The velocity of this turnover appears to be related to some 
physical properties of the nanoparticles, such as the size [180,181]. For example, 
Cartiera et al. [182] showed that PLGA nanoparticles appear to be localized in early 
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endosomes, Golgi apparatus and Endoplasmic reticulum, which are slow recycling 
compartments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 – Scheme showing the cellular excretion processes of nanoparticles (red arrows) along with their 
intracellular trafficking (blue arrows) and endocytosis mechanisms (green arrows). Figure adapted from 
reference [183].  
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3.7. Intracellular distribution of PAMAM(NH2)-RITC conjugates 
   
  Endocytosis is responsible for the transport of nanoparticles inside the cell 
through vesicles. Depending on their internalization route, nanomaterials can either be 
recycled and secreted from the cell through exocytosis, or trafficked to organelles, like 
lysosomes, Golgi complex and mitochondria (Figure 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41 – Intracellular transport of nanoparticles. Figure adapted from reference [184]. 
 
 The retention of nanomaterials inside vesicles is undesirable, because the 
maturation of vesicles into late endosomes and lysosomes is accomplished with a rapid 
acidification, with a pH decreasing from 6 to 4, and the recruitment of enzymes 
responsible for the degradation of the vesicular content. Polymers with amino groups, 
like PAMAM dendrimers, are known to escape from endosomes and lysosomes through 
the “proton-sponge effect” (Figure 42). In this effect, the polymer absorbs protons, 
inducing osmotic swelling of the endosome and, subsequently, its rupture [185,186].  
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Figure 42 – Illustration of the proton sponge effect, leading to endosome and lysosome escape. Cationic 
polymers, like PAMAM(NH2) dendrimers, are capable of sequestering protons by their amino groups. This 
process keeps the v-ATPase (proton pump) working, which leads to the retention of one Cl- ion and one 
water molecule per proton. Subsequently, this results in the rupture of the endosome or lysosome, and in 
the spillage and deposition of the particles in the cytoplasm. Figure adapted from reference [187].  
 
 Once released from the endolysosomal compartments, nanoparticles must travel 
through the cytoplasm, to reach the target, and have the desired biological response. 
However, little is known about the intracellular transport of nanoparticles. Researchers 
are trying to answer this question using different fluorescent probes and proteins, to 
study the intracellular transport of nanoparticles using multicolour fluorescence imaging 
[188]. So, in this study, since no PAMAM(NH2)-RITC conjugates were detected in the 
exosomes released by cells exposed to their presence, we were interested in knowing 
the localization/accumulation of the conjugates inside cells. To achieve this purpose, 
cells were exposed to the conjugates and were analysed using fluorescence microscopy 
and different fluorescent probes. MCF-7 cells were used in these studies for practical 
reasons.  
 Previously, during the conjugate uptake studies, accumulation of conjugates in 
the cell perinuclear region was already observed. As such, fluorescent probes for the 
endoplasmic reticulum and Golgi complex were used to see if there was co-localization 
of conjugates with these cellular structures since these are the organelles localized in 
that region of the cell. The results are exposed in Figure 43 and are coherent to the 
hypothesis that the PAMAM(NH2)-RITC conjugates accumulate in these cellular 
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structures. One can find some studies in the literature regarding the localization of 
nanoparticles inside cells. For example, Oddone et al. [149] showed that PAMAM-FITC 
conjugates demonstrated a similar perinuclear distribution in 4T1 breast tumour cells. 
Greulich et al. [186] demonstrated that silver nanoparticles presented also a perinuclear 
distribution in hMSCs but they were co-localized with the endo-lysosomal compartments 
and not with Golgi apparatus or endoplasmic reticulum. This shows that the intracellular 
distribution of nanoparticles is a very complex topic, depending on diverse factors, such 
as the properties of the nanomaterial.           
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Figure 43 – Co-localization and intracellular distribution of the PAMAM(NH2)-RITC conjugates in a MCF-7 
cell line. CellLightER-GFP is responsible for staining of endoplasmic reticulum (green fluorescent colour), 
Lectin HPA for staining of Golgi apparatus (green fluorescent colour) and Phalloidin for Actin (microtubules) 
(green fluorescent colour) staining. The red fluorescence emission comes from the RITC and the blue colour 
from DAPI staining.   
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Conclusions and Future Work 
 
Exosomes are considered a powerful tool in the bio- and nanomedicine fields. 
They can be used as biomarkers for several diseases, as well as for the inclusion of 
therapeutic cargo for treatment of several pathologies. However, they are still not very 
well understood and research about their biogenesis, properties and applications is 
greatly justified.  
In this thesis, the possibility of using exosomes derived from hMSCs as vehicles 
for dendrimers, namely of generation 4 (G4) poly(amidoamine) dendrimers with amino 
termini (PAMAM(NH2)), was explored. In particular, the hypothesis that exosomes could 
be loaded before their isolation from cells by simple cell exposure to a dendrimer-
containing solution was evaluated. Although, at the end, it was concluded that 
dendrimers accumulated in the cell perinuclear zone and were not excreted inside 
exosomes as expected, the following achievements were fulfilled: 
a) PAMAM(NH2)-RITC conjugates were successfully prepared and 
characterized, being possible to determine accurately the number of 
fluorochromes linked to the dendrimer; 
b)  the effect of pH in the stability of fluorescence emission of the PAMAM(NH2)-
RITC conjugates was studied showing that one can use RITC as a 
fluorochrome to track nanomaterials inside cells as its fluorescence intensity 
resists to acidic environments; the conjugation with the dendrimer did not 
affect the RITC fluorescence behaviour; 
c) the cytotoxicity of the PAMAM(NH2)-RITC conjugates was evaluated using 
hMSCs in culture; interestingly, the conjugation with RITC decreased the 
cytotoxicity of the dendrimer; 
d) the kinetics of PAMAM(NH2)-RITC conjugate cell uptake was studied 
revealing that a maximum in its cellular content was reached after 24h of 
culture; 
e) an exosome isolation protocol was established using a precipitation-based 
approach and the isolated exosomes were successfully characterized by 
DLS, TEM and acetylcholinesterase (AChE) activity; 
f) the localization/accumulation of the PAMAM(NH2)-RITC conjugates inside 
cells was analyzed revealing a co-localization with the Golgi complex and the 
endoplasmic reticulum. 
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In the future, it will be necessary to make a deeper characterization of the isolated 
exosomes with the use of other techniques, such as Tunable Resistive Pulse Sensing 
(TRPS), flow cytometry, Western-Blotting, Atomic Force Microscopy (AFM), etc., and 
fully accomplish the requirements imposed by ISEV for the characterization of these 
vesicles. Also, it would be very interesting to explore the use of other nanomaterials for 
incorporation in different sets of EVs, such as exosomes and microvesicles.  
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A. Supplementary data regarding the characterization of PAMAM(NH2)-RITC 
conjugates 
 
A1. Supplementary characterization data of PAMAM(NH2) G4-RITC conjugates 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A – I – Complete 1H NMR spectrum of the PAMAM(NH2) G4 in D2O at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A – II – Complete 1H NMR spectrum of RITC in D2O at 400 MHz. 
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Figure A – III – Complete 1H NMR spectrum of PAMAM(NH2) G4 - RITC in D2O at 400 MHz. 
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B. Supplementary data regarding the exosome isolation and characterization 
from cell culture medium 
 
 
 
Figure B – I – Distribution of the hydrodynamic size of the Total Isolation Exosome Reagent. The top graphic 
represents the size distribution by intensity, and the bottom represents the size distribution by volume. 
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C. Certificate of the Basics of Extracellular Vesicles Course  
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D. Manufacturer instructions of the Total Exosome Isolation Reagent  
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